PENDAHULUAN
A. Latar Belakang
Virus imunodifisiensi manusia (bahasa Inggris: human immunodeficiency virus; HIV)
adalah dua spesies lentivirus penyebab AIDS. Virus ini menyerang manusia dan
menyerang sistem kekebalan tubuh, sehingga tubuh menjadi lemah dalam melawan
infeksi jika virus ini terus menyerang tubuh lama kelamaan tubuh kita akan menjadi
lemah. Tanpa pengobatan, seorang dengan HIV bisa bertahan hidup selama 9-11 tahun
setelah terinfeksi, tergantung tipenya. Dengan kata lain, kehadiran virus ini dalam tubuh
akan menyebabkan penurunan sistem imun.Penyaluran virus HIV bisa melalui
penyaluran Semen (reproduksi), Darah, cairan vagina, dan ASI. HIV bekerja dengan
membunuh sel-sel penting yang dibutuhkan oleh manusia, salah satunya adalah Sel T
pembantu, Makrofaga, Sel dendritik.
Pada tahun 2014, the Joint United Nation Program on HIV/AIDS (UNAIDS)
memberikan rapor merah kepada Indonesia sehubungan penanggulangan HIV/AIDS.
Pasien baru meningkat 47 persen sejak 2005. Kematian akibat AIDS di Indonesia masih
tinggi, karena hanya 8 persen Orang Dengan HIV AIDS (ODHA) yang mendapatkan
pengobatan obat antiretroviral (ARV).Indonesia adalah negara ketiga di dunia yang
memiliki penderita HIV terbanyak yaitu sebanyak 640.000 orang, setelah China dan
India, karena ketiga negara ini memiliki jumlah penduduk yang banyak. Hanya saja
prevalensi di Indonesia hanya 0,43 persen atau masih di bawah tingkat epidemi sebesar
satu persen.
Pada tahun 1983, Jean Claude Chermann dan Françoise Barré-
Sinoussi dari Prancis berhasil mengisolasi HIV untuk pertama kalinya dari seorang
penderita sindrom limfadenopati. Pada awalnya, virus itu disebut ALV
(lymphadenopathy-associated virus) Bersama dengan Luc Montagnier, mereka
membuktikan bahwa virus tersebut merupakan penyebab AIDS. Pada awal tahun
1984, Robert Gallo dari Amerika Serikat juga meneliti tentang virus penyebab AIDS
yang disebut HTLV-III. Setelah diteliti lebih lanjut, terbukti bahwa ALV dan HTLV-III
merupakan virus yang sama dan pada tahun 1986, istilah yang digunakan untuk
menyebut virus tersebut adalah HIV, atau lebih spesifik lagi disebut HIV-1.
1
Tidak lama setelah HIV-1 ditemukan, suatu subtipe baru ditemukan di Portugal dari
pasien yang berasal dari Afrika Barat dan kemudian disebut HIV-2. Melalui kloning dan
analisis sekuens (susunan genetik), HIV-2 memiliki perbedaan sebesar 55% dari HIV-1
dan secara antigenik berbeda. Perbedaan terbesar lainnya antara kedua strain (galur)
virus tersebut terletak pada glikoprotein selubung. Penelitian lanjutan memperkirakan
bahwa HIV-2 berasal dari SIV (retrovirus yang menginfeksi primata) karena adanya
kemiripan sekuens dan reaksi silang antara antibodi terhadap kedua jenis virus tersebut.
Kedua spesies HIV yang menginfeksi manusia (HIV-1 dan -2) pada mulanya berasal dari
Afrika barat dan tengah, berpindah dari primata ke manusia dalam sebuah proses yang
dikenal sebagai zoonosis. HIV-1 merupakan hasil evolusi dari simian immunodeficiency
virus (SIVcpz) yang ditemukan dalam subspesies simpanse, Pan troglodyte troglodyte.
Sedangkan, HIV-2 merupakan spesies virus hasil evolusi strain SIV yang berbeda
(SIVsmm), ditemukan pada Sooty mangabey, monyet dunia lama Guinea-
Bissau. Sebagian besar infeksi HIV di dunia disebabkan oleh HIV-1 karena spesies virus
ini lebih virulen dan lebih mudah menular dibandingkan HIV-2. Sedangkan, HIV-2
kebanyakan masih terkurung di Afrika barat.
Berdasarkan susunan genetiknya, HIV-1 dibagi menjadi tiga kelompok utama, yaitu M,
N, dan O. Kelompok HIV-1 M terdiri dari 16 subtipe yang berbeda. Sementara pada
kelompok N dan O belum diketahui secara jelas jumlah subtipe virus yang tergabung di
dalamnya. Namun, kedua kelompok tersebut memiliki kekerabatan dengan SIV dari
simpanse. HIV-2 memiliki 8 jenis subtipe yang diduga berasal dari Sooty mangabey yang
berbeda-beda.
Apabila beberapa virus HIV dengan subtipe yang berbeda menginfeksi satu individu
yang sama, maka akan terjadi bentuk rekombinan sirkulasi (circulating recombinant
forms - CRF) (bahasa Inggris: circulating recombinant form, CRF). Bagian dari genom
beberapa subtipe HIV yang berbeda akan bergabung dan membentuk satu genom utuh
yang baru. Bentuk rekombinan yang pertama kali ditemukan adalah rekombinan AG dari
Afrika tengah dan barat, kemudian rekombinan AGI dari Yunani dan Siprus, kemudian
rekombinan AB dari Rusia dan AE dari Asia tenggara. Dari seluruh infeksi HIV yang
terjadi di dunia, sebanyak 47% kasus disebabkan oleh subtipe C, 27% berupa
CRF02_AG, 12,3% berupa subtipe B, 5.3% adalah subtipe D dan 3.2% merupakan CRF
AE, sedangkan sisanya berasal dari subtipe dan CRF lain.
Pada saat paling awalpun deteksi HIV dapat dilakukan dengan pemeriksaan darah,
walaupun tidak ada gejala apapun. Pada tahap kedua telah ada gejala klinis, misalnya
2
kulitnya jelek, gatal-gatal dan batuk pilek seperti flu biasa. Pada tahap ketiga akan
mengalami penurunan berat badan dan terkena TBC. Dan pada tahap keempat telah
mengalami komplikasi, sulit disembuhkan dan biasanya diikuti dengan kematian.
Umumnya, ada tiga tipe deteksi HIV, yaitu tes PCR, tes antibodi HIV, dan tes antigen
HIV. Tes reaksi berantai polimerase (PCR) merupakan teknik deteksi berbasis asam
nukleat (DNA dan RNA) yang dapat mendeteksi keberadaan materi genetik HIV di
dalam tubuh manusia. Tes ini sering pula dikenal sebagai tes beban virus atau tes
amplifikasi asam nukleat (HIV NAAT). PCR DNA biasa merupakan metode kualitatif
yang hanya bisa mendeteksi ada atau tidaknya DNA virus. Sedangkan, untuk deteksi
RNA virus dapat dilakukan dengan metode real-time PCR yang merupakan metode
kuantitatif. Deteksi asam nukleat ini dapat mendeteksi keberadaan HIV pada 11-16 hari
sejak awal infeksi terjadi. Tes ini biasanya digunakan untuk mendeteksi HIV pada bayi
yang baru lahir, namun jarang digunakan pada individu dewasa karena biaya tes PCR
yang mahal dan tingkat kesulitan mengelola dan menafsirkan hasil tes ini lebih tinggi
bila dibandingkan tes lainnya.
Untuk mendeteksi HIV pada orang dewasa, lebih sering digunakan tes antibodi HIV
yang murah dan akurat. Seseorang yang terinfeksi HIV akan menghasilkan antibodi
untuk melawan infeksi tersebut. Tes antibodi HIV akan mendeteksi antibodi yang
terbentuk di darah, saliva (liur), dan urin. Sejak tahun 2002, telah dikembangkan suatu
penguji cepat (rapid test) untuk mendeteksi antibodi HIV dari tetesan darah ataupun
sampel liur (saliva) manusia. Sampel dari tubuh pasien tersebut akan dicampur dengan
larutan tertentu. Kemudian, kepingan alat uji (test strip) dimasukkan dan apabila
menunjukkan hasil positif maka akan muncul dua pita berwarna ungu kemerahan.Tingkat
akurasi dari alat uji ini mencapai 99.6%, namun semua hasil positif harus dikonfirmasi
kembali dengan ELISA. Selain ELISA, tes antibodi HIV lain yang dapat digunakan
untuk pemeriksaan lanjut adalah Western blot.
Tes antigen dapat mendeteksi antigen (protein P24) pada HIV yang memicu respon
antibodi. Pada tahap awal infeksi HIV, P24 diproduksi dalam jumlah tinggi dan dapat
ditemukan dalam serum darah. Tes antibodi dan tes antigen digunakan secara
berkesinambungan untuk memberikan hasil deteksi yang lebih akurat dan lebih awal. Tes
ini jarang digunakan sendiri karena sensitivitasnya yang rendah dan hanya bisa bekerja
sebelum antibodi terhadap HIV terbentuk.
Kesemua cara di atas mendeteksi virusnya, tetapi cara paling murah adalah tes CD4 yang
hanya Rp 100,000 lebih di RS Kanker. CD4 tidak mengetes kehadiran virus HIVnya,
3
atau antibodi spesifik yang melawan HIV, CD4 mengukur sistem imunitas pasien.
Sebelumnya jika CD4 belum mencapai nilai tertentu, walaupun diketahui keberadaan
virus HIV, maka belum dilakukan pengobatan apapun, tetapi sekarang ini jika sudah
diketahui keberadaan virus HIV, maka berapapun nilai CD4 harus dilakukan
pengobatan.Di Indonesia, dimana masalah dana menjadi kendala, maka tes CD4 sudah
cukup memadai untuk deteksi awal kemungkinan keberadaan virus HIV. Dan perlu
diingat bahwa HIV belum tentu menjadi AIDS dengan pengobatan yang adekuat. CD4
juga berguna sebagai indikasi awal keberadaan kanker atau segala hal yang berhubungan
dengan sistem imunitas pasien. Jika CD4 telah mencapai nilai tertentu, maka perlu
dilakukan tes CD8.
B. Rumusan Masalah
1. Apa yang d maksud dengan HIV/AIDS?
2. Bagaimakah trend HIV/AIDS saat ini?
3. Apa saja isue yang berkembang di masyarakat tentang HIV/AIDS?
C. Tujuan Penulisan
1. Untuk memenuhi salah satu persyaratan akademik mata kuliah KEPERAWATAN
HIV/AIDS
2. Untuk memahami apa yang di maksud dengan HIV/AIDS
3. Untuk mengetahui tren yang berkembang di masyarakat tentang HIV/AIDS
4. Untuk mengetahui isue-isue tentang HIV/AIDS yang berkembang di masyarakat
BAB II
PEMBAHASAN
A. Pengertian HIV/AIDS
4
HIV (human immunodeficiency virus) adalah virus yang merusak sistem kekebalan
tubuh, dengan menginfeksi dan menghancurkan sel CD4. Semakin banyak sel CD4 yang
dihancurkan, kekebalan tubuh akan semakin lemah, sehingga rentan diserang berbagai
penyakit. Infeksi HIV yang tidak segera ditangani akan berkembang menjadi kondisi
serius yang disebut AIDS (Acquired Immune Deficiency Syndrome). AIDS adalah
stadium akhir dari infeksi virus HIV. Pada tahap ini, kemampuan tubuh untuk melawan
infeksi sudah hilang sepenuhnya.Sampai saat ini belum ada obat untuk menangani HIV
dan AIDS. Akan tetapi, ada obat untuk memperlambat perkembangan penyakit tersebut,
dan dapat meningkatkan harapan hidup penderita.
Virus HIV terbagi menjadi 2 tipe utama, yaitu HIV-1 dan HIV-2. Masing-masing tipe
terbagi lagi menjadi beberapa subtipe. Pada banyak kasus, infeksi HIV disebabkan oleh
HIV-1, 90% di antaranya adalah HIV-1 subtipe M. Sedangkan HIV-2 diketahui hanya
menyerang sebagian kecil individu, terutama di Afrika Barat.
Infeksi HIV dapat disebabkan oleh lebih dari 1 subtipe virus, terutama bila seseorang
tertular lebih dari 1 orang. Kondisi ini disebut dengan superinfeksi. Meski kondisi ini
hanya terjadi kurang dari 4% penderita HIV, risiko superinfeksi cukup tinggi pada 3
tahun pertama setelah terinfeksi.
Berdasarkan data Kementerian Kesehatan RI, selama tahun 2016 terdapat lebih dari 40
ribu kasus infeksi HIV di Indonesia. Dari jumlah tersebut, HIV paling sering terjadi pada
heteroseksual, diikuti lelaki seks lelaki (LSL), dan pengguna NAPZA suntik (penasun).
Di tahun yang sama, lebih dari 7000 orang menderita AIDS, dengan jumlah kematian
lebih dari 800 orang.
Data terakhir Kemenkes RI menunjukkan, pada rentang Januari hingga Maret 2017 saja
sudah tercatat lebih dari 10.000 laporan infeksi HIV, dan tidak kurang dari 650 kasus
AIDS di Indonesia.
B. Trend HIV/AIDS
Tren penularan HIV/AIDS beralih yaitu dari pecandu narkoba menjadi perilaku
heteroseksual. Dari perilaku heteroseksual tersebut, jumlah laki-laki positif HIV/AIDS
lebih tinggi ketimbang wanita, dengan usia dominan yaitu 20-29 tahun. Koordinator
Bidang Ilmiah Perteuan Nasional (Pernas) AIDS IV, Yanri Subrongto mengatakan tren
penularan berubah karena berbagai faktor, dari faktor heterokseksual sendiri, yaitu
tentang Pekerja Seks Komersial (PSK). Ini disebabkan karena “PSK bisa pergi ke mana-
mana tanpa dibatasi aturan, dan bisa saja membawa virus. Hal inilah yang memicu
5
peningkatan kasus HIV/AIDS," paparnya dalam Konferensi Pers Pertemuan Nasional
AIDS IV di Yogyakarta, Rabu(21/9).
Data yang ada juga memberi informasi bahwa kelompok heteroseksual menjadi
kelompok paling rentan atas kasus AIDS di Indonesia. Selama periode 1987-2016,
tercatat ada 58.846 kasus dari kelompok heteroseksual.
Kelompok kedua yang berisiko tinggi adalah IDU (injecting drug user) yang mencapai
9.080 kasus. Sayangnya, ada lebih dari 11 ribu kasus yang belum diketahui risiko
penyebab kasusnya.
Kelompok heteroseks masih menjadi kelompok utama sebagai kelompok yang paling
riskan dari kasus AIDS. Sekalipun telah menunjukkan tren yang menurun setelah 2013,
angkanya masih cukup tinggi. Pada 2010, tercatat jumlah kasus AIDS yang dilaporkan
karena hubungan heteroseksual sebanyak 4.715. Jumlah ini meningkat menjadi 5.545
pada 2016.
Perilaku seksual sebagai faktor risiko terbesar dalam paparan HIV-AIDS menegaskan
kembali soal problema promikuitas, atau hubungan seksual antara sejumlah pria dan
wanita tanpa ada aturan yang mengikat. Seks dengan lebih dari satu pasangan, tanpa
pelindung, meningkatkan risiko HIV-AIDS.
Sampai saat ini masih banyak informasi hoax yang beredar mengenai penularan HIV-
AIDS. Hal ini berimbas pada sikap masyarakat terhadap orang dengan HIV-AIDS
(ODHA). Ya, stigma terhadap ODHA pun menjadi negatif. Nyatanya, penularan HIV-
AIDS tidak semudah dari memakai pakaian yang sama atau berbagi makanan dengan
ODHA, seperti yang ramai beredar dalam pesan berantai.
Menurut dr Teguh Karyadi, SpPD, KAI, dari RS Cipto Mangunkusumo, perlu kedekatan
yang luar biasa antara seorang pengidap dengan orang lain agar bisa terinfeksi karena
hanya paparan cairan tubuh seperti darah dan cairan kelamin saja yang bisa menularkan
virus.“Penularan HIV itu tidak mudah. Harus betul-betul yang terpercik cairan tubuh atau
karena sesuatu invasif karena perilaku kita sendiri,” papar dr Teguh kepada detik Health
beberapa waktu lalu
C. Isue HIV/AIDS
1. Terompet tahun baru
Pergantian tahun identik dengan pesta kembang api dan tiup-tiup terompet. Beberapa
waktu lalu pun ramai beredar pesan berantai yang menyebutkan bahwa virus HIV bisa
menyebar lewat terompet.
6
2. Baju bekas
Pada sekitar tahun 2015, Menteri Perdagangan saat itu, Rachmat Gobel, sempat
mendapat kecaman dari aktivis Indonesia AIDS Coalition (IAC). Gobel menyebut
pakaian bekas impor berbahaya karena bisa menularkan HIV (Human
Imunodeficiency Virus).
3. Makanan kalengan
Pernah beredar kabar bahwa ada virus HIV-AIDS di dalam kemasan makanan
kalengan impor. Pesan yang dikirim melalui broadcast message blackberry messenger
tersebut mengatakan bahwa para pekerja positif HIV-AIDS tempat makanan tersebut
dibuat memasukkan darah mereka ke dalam kemasan makanan tersebut. Akan tetapi
hal ini di tepis oleh dr Roy Sparringa yang kala itu menjabat sebagai Kepala Badan
Pengawasan Obat dan Makanan (BPOM). dr Roy mengatakan bahwa BPOM tidak
pernah menemukan hal-hal seperti yang disebutkan dalam pesan berantai tersebut,
termasuk kandungan darah dan virus HIV. Selain itu menurut dr Roy, virus HIV tidak
akan mampu bertahan hidup jika sudah keluar dari tubuh manusia.
4. Pembalut
Lagi-lagi sangat tidak masuk akal virus HIV bisa menular melalui produk pembalut
yang dijual di pasaran. Lagipula jika pembalut yang dibelinya kotor, terdapat bercak
darah seperti pembalut yang sudah pernah dipakai, tentu tidak ada orang yang mau
menggunakannya.
5. Bangku bioskop
Jarum suntik yang disebut-sebut berisi virus HIV juga pernah dipasang di bangku
bioskop. Jika ada orang yang duduk di bangku tersebut, maka ia otomatis akan
tertular oleh virus tersebut. dr Sarsanto Wibisono Sarwono, SpOG menyebutkan
bahwa rasanya sulit menularkan virus HIV-AIDS. Ini karena darah yang terinfeksi
harus benar-benar masuk ke dalam pembuluh darah seseorang. “Kalau beneran ada
jarum di kursi bioskop, misal ada yang menduduki, jarumnya kan tertahan sama kain
bajunya. Kalau celana juga kan biasanya tebal, itu juga udah susah kena ke kulit,”
imbuh dr Sarsanto.
7
BAB III
PENUTUP
A. Kesimpulan
Virus imunodifisiensi manusia (bahasa Inggris: human immunodeficiency virus; HIV)
adalah dua spesies lentivirus penyebab AIDS. Virus ini menyerang manusia dan
menyerang sistem kekebalan tubuh, sehingga tubuh menjadi lemah dalam melawan
8
infeksi jika virus ini terus menyerang tubuh lama kelamaan tubuh kita akan menjadi
lemah. Isue yang beredar dimasyarakat kadang tidak dapat di percaya. Penyebaran
HIV/AIDS hanya bisa terjadi dengan media darah, ASI, ataupun air mani. Sehingga
isueisue penyebaran HIV/AIDS dari terompet, kursi bioskop, pembalut dll adalah salah
B. Saran
Setiap berita yang kita peroleh haruslah dicari dengan tepat kebenarannya dan tidak asal
mempercayainya. Penyakit HIV itu tak seganas yang dibayangkan, tak seperti hepatitis
yang penularannya cepat, namun apabila terinfeksi dampaknya akan sangat luar biasa.
DAFTAR PUSTAKA
Murni, suzana, dkk.2016.Hidup dengan HIV-AIDS,terbitan 2. Jakarta:Yayasan Spiritia
http://nationalgeographic.co.id/berita/2011/09/tren-penularan-hivaids-beralih-pada-
heteroseksual#
https://turnbackhoax.id/2018/01/04/edukasi-isu-isu-mengenai-media-penyebaran-hiv-aids/
https://www.alodokter.com/hiv-aids/ dr. Tjin Willy/2018
9
hatti, et al. (2016). Current Scenario of HIV/AIDS, Treatment Options, and Major Challenges
with Compliance to Antiretroviral Therapy. Cureus, 8(3), pp. e515.
Simon, et al. (2006). HIV/AIDS Epidemiology, Pathogenesis, Prevention, and Treatment.
Lancet, 368(9534), pp. 489-504.
World Health Organization (2018). HIV/AIDS.
Kementerian Kesehatan Republik Indonesia (2017). Direktorat Jenderal Pencegahan dan
Pengendalian Penyakit. Laporan Perkembangan HIV-AIDS & Penyakit Infeksi Menular
Seksual (PIMS) Triwulan 1 Tahun 2017.
LAMPIRAN
1.1. Jurnal Ver. English
HIV Transmission
George M. Shaw1 and Eric Hunter2
Abstract
10
HIV-1 transmission results from virus exposure at mucosal surfaces or from percutaneous
inoculation. Because such exposures in humans are inaccessible to direct analysis, our
understanding of the transmission event must necessarily come from insights gleaned from
studies of HIV-1 epidemiology, viral and host genetics, risk factor and behavior analyses,
animal models, human explant tissues, and in vitro studies of virus-target cell interactions. In
this article, we explore themes that connect these varied aspects of HIV-1 infection with the
ultimate goal of understanding the molecular basis of HIV-1 transmission.
11
TRANSMISSION ROUTES AND RISKS FOR HIV-1 INFECTION
In 2009, an estimated 2.6 million people globally became newly infected by HIV-1 (UNAIDS
2010). This represents a reduction in new infections by 21% compared with 1997 when
incident infections peaked. But declining HIV-1 incidence rates have not been uniform across
all regions and risk groups, highlighting the importance of different transmission routes and
risk behaviors in facilitating HIV-1 transmission. The most extreme example is in Eastern
Europe and Central Asia where HIV-1 prevalence tripled between 2001–2009 as a
consequence of concentrated epidemics associated with sex work, drug use, and men who
have sex with men (MSM) (UNAIDS 2010). Table 1 summarizes the risks for HIV-1
transmission associated with different transmission routes and their relative contributions to
HIV-1 prevalence worldwide. What is evident from these estimates is that heterosexual
transmission is responsible for nearly 70% of HIV-1 infections worldwide with the remainder
largely attributable to MSM, maternal-infant infection, and injection drug use. This is the
case despite the fact that transmission probability per coital act is lowest for heterosexual
exposures (1 in 200–1 in 3000) (Hladik and McElrath 2008; McElrath et al. 2008). However,
two recent meta-analyses of HIV-1 incidence and prevalence data (Powers et al. 2008; Boily
et al. 2009) suggest a far wider range in HIV-1 transmission risk for heterosexual exposures
depending on confounding risk factors such as genital ulcer disease, male circumcision, HIV
disease stage, and exposure route. For example, penile-vaginal transmission of HIV-1 was
reported at a frequency as high as 1 in 10 exposures and penile-anal transmission as high as 1
in 3 depending on confounding risk cofactors (Powers et al. 2008). Thus, the commonly
quoted risk estimate for heterosexual HIV-1 acquisition of 1 in 1000 exposures must be
considered a lower bound.
Table 1.
Transmission routes and risks for HIV-1 infection
Ectocervix Squamous,
nonkeratinized
12
HIV Anatomical Type of epithelium Transmission Transmission Estimated
invasion sublocation medium probability contribution
site per exposure to HIV cases
event worldwide
Other Various
Other Various
13
HIV Anatomical Type of epithelium Transmission Transmission Estimated
invasion sublocation medium probability contribution
site per exposure to HIV cases
event worldwide
Adapted from the 2010 UNAIDS/WHO AIDS epidemic update and Hladik and McElrath
(2008).
a. Includes men having sex with men (MSM), bisexual men, and heterosexual men.
b. Includes MSM, bisexual men, and women infected via anal receptive intercourse.
c. Mother-to-child transmission.
d. Mostly intravenous drug use, but includes infections by transfusions and health-care-
related accidents. GI, gastrointestinal.
Socioeconomic factors can also influence HIV-1 transmission indirectly. El-Sadr and
colleagues have suggested that in the United States, the risk of acquiring HIV-1 infection is
defined more by a person’s “sexual network” than by their individual risk behaviors, with the
former influenced primarily by socioeconomic factors (El-Sadr et al. 2010). On a global
14
basis, HIV-1 transmission estimates per coital act vary significantly between high-income
countries, where male to female (MTF) transmission estimates are 0.08% and female to male
(FTM) rates are 0.04%, and low-income countries, where MTF and FTM transmission rates
are 0.38% and 0.3%, respectively (Powers et al. 2008; Boily et al. 2009). These differences
may in part reflect the relative frequency of HIV serodiscordant couples in the two settings
since it has been estimated that they represent the source of a majority of adult infections in
many low-income countries (Dunkle et al. 2008).
Viral load (vL) in the transmitting partner plays a major role in determining the risk of HIV-1
transmission from one individual to another. Although vL likely affects all modes of
transmission, it has been best characterized in HIV-1 discordant couples, in which as much as
a 2.5-fold increase in transmission was observed for every 10-fold increase in vL (Quinn
2000; Fideli et al. 2001). Moreover, although vL in genital secretions may not correlate
directly with that in the blood, partners with plasma vL less than 1000 rarely transmitted to
their partners (Quinn et al. 2000; Fideli et al. 2001). The recent observation (HIV Prevention
Trials Network Study 052, unpubl.) that antiretroviral treatment of the positive partner of
discordant couples can result in a 96% reduction in transmission is consistent with this
finding (Cohen et al. 2011b). The clinical stage of infection (acute vs. middle vs. late) in the
transmitting partner can also play a key role in defining the efficiency of transmission, with
the risk of infection from individuals with acute or early infection being higher than that in
established infection (Wawer et al. 2005; Brenner et al. 2007; Powers et al. 2008; Miller et al.
2010). This likely reflects the high vLs observed in acute infection, a lack of neutralizing
antibodies that may inactivate circulating virus in established infection, and clonal
amplification of highly fit viruses in acute infection that are especially suitable for initiating
productive infection (Richman et al. 2003; Wei et al. 2003; Wawer et al. 2005; Keele et al.
2008; Cohen et al. 2011a). Indeed, in the Indian rhesus macaque model of SIV transmission,
SIV in the plasma from animals in the acute stage of infection had a specific infectivity up to
750 times greater than that of virus in the plasma from chronically infected animals (Ma et al.
2009).
The efficiency of HIV-1 transmission can be modulated by still other factors, including
sexually transmitted diseases, particularly those that result in genital inflammation and ulcers,
which can elevate HIV shedding into the genital tract and can increase infection susceptibility
by two- to 11-fold (Galvin and Cohen 2004); pregnancy, during which a greater than twofold
increase in HIV acquisition risk has been observed (Gray et al. 2005); and circumcision,
which in a series of clinical trials has been shown to decrease transmission acquisition risk in
the male partner by 60% (Auvert et al. 2005; Bailey et al. 2007; Gray et al. 2007; Quinn
2007).
15
replication and diversification (Keele et al. 2008; Lee et al. 2009). During the eclipse phase,
which is clinically silent, virus is propagated in CD4+ T cells in mucosa, submucosa, draining
lymphatics, and perhaps to a modest extent in gut-associated lymphoid tissue (GALT) and
systemic lymphatic tissues (Haase 2010). Once virus becomes detectable in blood plasma, it
increases exponentially (Ribeiro et al. 2010) as a consequence of explosive replication in
GALT and peripheral lymphoid tissue compartments (Veazey et al. 1998; Guadalupe et al.
2003; Brenchley et al. 2004; Mehandru et al. 2004; Li et al. 2005b; Mattapallil et al.
2005; Haase 2010). Fiebig stages I–VI reflect the ordered appearance in the plasma of HIV-1
viral RNA (Fiebig I), viral p24 antigen (Fiebig II), and virus-specific antibodies detectable
first by recombinant protein-based enzyme-linked immunosorbant assay (Fiebig III), and then
by Western immunoblotting (indeterminant banding pattern: Fiebig IV; diagnostic banding
pattern but missing p31 reactivity: Fiebig V; diagnostic banding pattern with p31 reactivity:
Fiebig VI). The average durations of the eclipse phase and Fiebig stages along with estimated
95% confidence intervals are shown in the inset of Figure 1. Diagnosing HIV-1 infection as
soon as possible after the transmission event is important clinically to ensure the safety of
blood for transfusion and of body organs for transplantation. It is also important for
preventing forward transmission of the virus from index patients to their contacts. Current
HIV-1 nucleic acid tests based on different amplification platforms can detect viral sequences
qualitatively at 1–5 copies per milliliter of plasma (Palmer et al. 2003; Nugent et al. 2009)
and quantitatively at levels exceeding 50 copies per milliliter plasma (Damond et al. 2010).
Alternatively, a recently approved fourth-generation combined p24 antigen-antibody test can
detect HIV-1 at viral loads exceeding 10,000 virions per milliliter plasma (Eshleman et al.
2009; Cohen et al. 2011a). Thus, commercially available p24 antigen tests can detect HIV-1
infection approximately 1 wk before the first detection of anti-HIV antibodies, and vRNA
tests can detect HIV-1 infection approximately 1 wk before that (Fig. 1). There are well-
documented examples of HIV-1 antibody seroconversion as late as 6 mo or more after an
exposure event but such cases are rare (Ridzon et al. 1997); what is more remarkable is the
consistency in the timing of appearance of viral and host markers of infection (Fig. 1) despite
the different cells and tissues that are involved in the transmission process at the different
sites of HIV-1 invasion (Table 1).
Figure 1.
Laboratory staging and natural history of acute and early HIV-1 infection. The average
16
durations and 95% confidence intervals (parentheses) of the eclipse phase and Fiebig stages
(Fiebig et al. 2003) of acute infection are shown in the inset.
18
HIV-1 viruses. All Envs were biologically functional with respect to virus entry and all were
CD4 dependent. Fifty-four of 55 Envs were CCR5-tropic and one was CCR5/CXCR4 dual-
tropic. Transmitted/founder Envs showed neutralization sensitivity profiles typical of tier 2 or
3 primary virus strains (Li et al. 2005a). Thus, the findings from this study provided new
clarity to the quantitative and molecular aspects of HIV-1 transmission.
Based on the empirical findings described by Keele et al. (2008) and the mathematical model
of early HIV-1 replication and diversification developed by Korber, Perelson, and colleagues
(Keele et al. 2008; Lee et al. 2009), a conceptual framework for describing HIV-1
transmission and early diversification was developed (Fig. 2). Direct evidence in support of
this transmission model and the notion that actual transmitted/founder viral genomes could be
identified unambiguously by SGA-direct amplicon sequencing came from three additional
sets of studies: Indian rhesus macaque monkeys inoculated intra-rectally with low-dose
SIVmac251 in which viruses in the inoculum and in newly infected animals were found to be
identical in env gene sequences (Keele et al. 2009); human transmission pairs in which HIV-
1 env and full-length viral genomic sequences were found to be identical in donors and
recipients (Haaland et al. 2009; J. Salazar-Gonzalez and G. Shaw, unpubl.); and 454 deep
sequencing of tens of thousands of plasma vRNA/cDNA HIV-1 genomes from three acutely-
infected human subjects, demonstrating productive clinical infection by the same
transmitted/founder viruses as identified by SGA-direct amplicon sequencing (Fischer et al.
2010). Of note, the terms “transmitted/founder sequence” and “transmitted/founder virus” are
used to designate the coalescent or consensus sequence of a low-diversity virus lineage in
acutely infected humans or monkeys because such sequences correspond literally to founder
sequences that are responsible for establishing productive clinical infection. In most
instances, the founder sequence corresponds to the actual transmitted sequence. Exceptions
are likely uncommon and include founder sequences that differ from the actual transmitted
sequence by one or a few nucleotides because of reverse transcriptase errors in the initial one
or two replication cycles or, more substantially, because of recombination between
copackaged heterozygous RNA genomes during reverse transcription in the first infected cell
(Lee et al. 2009).
19
Figure 2.
HIV-1 transmission model. HIV-1 virions that breach the mucosa may have different fates.
Empirical measurements of virus replication and diversification, together with a mathematical
model of random virus evolution, allow for a precise molecular identification of
transmitted/founder viruses that are responsible for productive clinical infection (Keele et al.
2008; Lee et al. 2009). R0 is the reproductive ratio. R0 > 1 leads to productive clinical
infection, whereas R0 < 1 results in an extinguished infection.
Additional studies of acutely infected human cohorts using SGA-direct amplicon sequencing
provided further insights into the HIV-1 population bottleneck. These studies focused on
heterosexual transmission in sub-Saharan Africa (Abrahams et al. 2009; Haaland et al. 2009;
J Baalwa and G Shaw, unpubl.), MSM transmission in the United States (Kearney et al.
2009; Li et al. 2010), injection drug use transmission in Canada, Russia, and Thailand (Bar et
al. 2010; Masharsky et al. 2010; K Bar and G Shaw, unpubl.), and most recently, maternal-
infant transmission in Malawi (Russell et al. 2011). Each of these studies provided
unambiguous molecular identification of transmitted/founder viral genes or genomes and
precise estimates of the numbers of transmitted/founder viruses responsible for productive
clinical infection. Two studies used SGA-direct amplicon sequencing to identify full-length
transmitted founder genomes (Salazar-Gonzalez et al. 2009; Li et al. 2010). A summary of all
of these studies, which included over 300 acutely infected subjects, indicated that
approximately 80% of heterosexual subjects are productively infected by a single viral
genome (Keele et al. 2008; Abrahams et al. 2009; Haaland et al. 2009) and approximately
60% and 40% of MSM and IDUs, respectively, are productively infected by single genomes.
20
The range in transmitted/founder genomes that resulted in productive clinical infection in
these studies was 1–16, and not surprisingly, the highest numbers were in IDUs (Bar et al.
2010; Li et al. 2010; Masharsky et al. 2010; K Bar and G Shaw, unpubl.). For maternal-infant
transmissions, 68% were productively infected by a single virus and this varied depending on
intrauterine versus intrapartum transmission routes (Russell et al. 2011). The observed
differences in the multiplicity of viral infection associated with different routes of
transmission roughly parallels the relative risk of clinical infection on a per event basis (Table
1). As predicted for transmitted/founder viruses, transmitted/founder env genes were
invariably biologically functional and full-length genomes were invariably replication
competent (Keele et al. 2008; Salazar-Gonzalez et al. 2009; Li et al. 2010; C Ochsenbauer, J
Kappes, and G Shaw, unpubl.). Interestingly, in studies of primarily heterosexual
transmission (Keele et al. 2008; Abrahams et al. 2009), in those individuals in which multiple
viruses initiated infection, the number of infecting variants did not follow a Poisson
distribution. This finding is inconsistent with each variant being transmitted independently
and with low probability and suggests that transmission cofactors such as sexually
transmitted infections (STIs) or hormonal contraceptives lower the barrier to transmission
(Abrahams et al. 2009; Haaland et al. 2009). This interpretation is consistent with the model
portrayed in Figure 2, in which virus transmission can fail at multiple steps following
inoculation onto a mucosal surface. Thus, STIs including genital ulcer disease may abrogate
the barrier imposed by an intact mucosa by inducing breaks in the epithelial lining, thereby
allowing more virus variants to initiate infection in the mucosal tissue. Alternatively,
inflammation induced by STIs could increase the availability of activated CD4 cells required
to initiate a spreading infection, in this way allowing infections that would have failed
because of lack of available target cells to expand. Finally, recent SGA comparisons of the
genetic diversity of HIV in the genital tract of the transmitting partner to the
transmitted/founder virus in the acutely infected partner argue against genital
compartmentalization of specific viral variants in the donor as being responsible for origin of
the population bottleneck, consistent with the model presented in Figure 2 (D Boeras, and E
Hunter, unpubl.).
21
The first suggestion that HIV-1 transmission might select for traits other than coreceptor
usage came from a genetic comparison of the viral env sequences from eight subtype C HIV-
1 transmission pairs (Derdeyn et al. 2004). This study was conducted prior to reports
describing SGA and thus carries the caveat that molecular clones of env could have contained
in vitro generated artifacts from Taq polymerase misincorporation or recombination.
Nonetheless, in each subject pair, regardless of whether virus was transmitted MTF or FTM,
the newly transmitted viruses encoded statistically shorter and less glycosylated V1–V4
regions than did envs from the chronically infected partner. This finding raised the possibility
that more compact Env glycoproteins might interact more efficiently with relevant target cells
in the genital mucosa. This observation was subsequently confirmed using SGA methods in
an independent cohort of 10 subtype C transmission pairs (Haaland et al. 2009). Similar
results, albeit with non-SGA methods, were obtained in studies comparing Envs from subtype
A HIV-1 acutely infected sex workers to a database of matched chronic virus sequences
(Chohan et al. 2005) and 13 subtype D and A transmission pairs from the Rakai district of
Uganda (Sagar et al. 2009). Interestingly, such differences in acute versus chronic Envs were
not seen in studies of recently transmitted subtype B HIV-1 heterosexual or MSM infections,
suggesting that subtype differences in the virus or maturity of the epidemics may influence
the contribution of such a phenotype to HIV-1 transmission (Chohan et al. 2005; Frost et al.
2005; Wilen et al. 2011a). Most recently, Korber and colleagues (Gnanakaran et al. 2011)
compared over 7000 SGA-derived env gp160 sequences from 275 acutely or chronically
infected subtype B subjects and observed statistically robust signatures comprising single
amino acids, glycosylation motifs, and multisite patterns of clustered amino acids. These
included signatures near the CCR5 coreceptor binding surface, near the CD4-binding site, in
the cytoplasmic domain of gp41, and in the signal peptide. The motif with highest statistical
significance was at amino acid position 12 in the signal peptide, which may affect Env
expression and incorporation of Env into virions (Asmal et al. 2011). The second most
significant signature was at amino acid position 413–415, which affected a glycan involved in
escape from antibody neutralization. How these changes might affect HIV-1 transmission is
currently unknown.
A second approach to analyzing transmitted HIV-1 genomes for distinguishing properties is
by phenotypic characterization. It has been difficult to link sequence differences observed
between chronic and acute Envs, even within transmission pairs, to a distinct phenotypic
property that might influence transmission other than CCR5 tropism. In an analysis of
Zambian subtype C transmission pairs (Derdeyn et al. 2004), it was found that Envs from the
newly transmitted viruses retained sensitivity to neutralization by the partner’s antibodies and
in fact were more sensitive on average than Env variants derived from the transmitting
partner (Derdeyn et al. 2004). This characteristic coupled with shorter variable loops in early
viruses led to the hypothesis that transmissibility was linked to loss of Env modifications
required for neutralization resistance in the chronically infected host but dispensable in the
immunologically naïve partner. Despite this, the acute Envs were not generally more sensitive
to neutralization by either pooled HIV-1–positive sera or to a majority of broadly neutralizing
antibodies (Derdeyn et al. 2004; Li et al. 2006). Moreover, the acute and chronic Envs had
similar requirements for high CD4 and CCR5 levels on target cells and they showed
comparable utilization of CCR5 chimeric proteins and alternative coreceptors (Isaacman-
Beck et al. 2009; Alexander et al. 2010). Also, following up on genetic signatures of virus
transmission identified by Korber and colleagues (Gnanakaran et al. 2011), Asmal et al.
(2011) characterized the phenotypic effects of the position 12 polymorphism in the Env
leader sequence, which was found to be an enriched motif in transmitted/founder viruses.
Experiments showed an association between a positive amino acid (histidine) at position 12
22
and higher Env expression, higher virion Env incorporation, and higher virion infectivity
compared with control viruses.
The first biological analysis of complete HIV-1 subtype B transmitted/founder env genes
(Keele et al. 2008), and of subtype B and C transmitted/founder full-length viral genomes
(Salazar-Gonzalez et al. 2009; Li et al. 2010), showed these viruses to be uniformly CD4
dependent and CCR5 or CCR5/CXCR4 dual tropic. These findings thus revealed that CCR5
tropism is a property of the transmitted virus itself and not a phenotype that evolves in the
initial days and weeks of infection. Similarly, transmitted/founder viruses were found to show
neutralization sensitivity patterns typical of tier 2 or 3 primary virus strains (Li et al. 2005a)
with V3 and coreceptor binding surface regions well protected from binding by neutralizing
monoclonal or polyclonal HIV-1 antibodies (Keele et al. 2008). Again, these were properties
of the transmitted/founder virus at or near the moment of virus transmission and were not
properties that evolved in early infection. Subtype B and C transmitted/founder genomes
encoded viruses that replicated efficiently in primary human CD4+ T cells but much less well
in monocyte-derived macrophages (Salazar-Gonzalez et al. 2009; Li et al. 2010; C
Ochsenbauer, J Kappes, and G Shaw, unpubl.), consistent with results obtained with Env
pseudotyped viruses (Isaacman-Beck et al. 2009). These observations were extended to
subtype A transmitted/founder viruses, which replicated efficiently in primary human CD4 + T
cells but very poorly in monocyte-derived macrophages. Interestingly, a substantial
proportion of subtype D transmitted/founder viruses replicated efficiently in both CD4 + T
cells and macrophages (J Baalwa and G Shaw, unpubl.), which may correlate with enhanced
neuropathogenesis of subtype D viruses more generally (Sacktor et al. 2009). Again, these
findings described features of transmitted/founder viruses at or near the moment of
transmission and not virus properties that evolved in the newly infected host. Thus, these
findings have particular relevance to rational vaccine design efforts and studies of virus
transmission in general. With respect to animal models and human tissue explant studies of
HIV-1 transmission, the results suggest that tissue macrophages may not play a significant
role in HIV-1 transmission and that prototypic macrophage-tropic HIV-1 strains such as BaL,
ADA, and YU2 may not be best suited as challenge viruses.
Swanstrom and colleagues (Russell et al. 2011) recently examined the genetic and biological
basis of the HIV-1 population bottleneck in mother-infant HIV-1 transmission in subtype C
infections in Malawi. They used SGA techniques to characterize 19 transmission pairs, of
which 10 involved intrauterine transmission and nine intrapartum transmission. There was a
stringent transmission bottleneck in each case. Thirteen of 19 transmissions were estimated to
be from a single virus. Intrapartum (but not intrauterine) transmissions were characterized by
transmitted/founder Envs that were shorter and had fewer potential amino-linked glycans in
V1–V5. Mother and infant viruses were similar, however, in their sensitivity to soluble CD4,
a panel of neutralizing monoclonal antibodies, and to autologous and heterologous polyclonal
antibody neutralization. Thus, a distinguishing transmission phenotype was not evident.
The most comprehensive and systematic assessment thus far of the biology of
transmitted/founder Envs compared with chronic HIV-1 Envs has been conducted by Doms
and colleagues (Wilen et al. 2011a). These investigators compared the biological activity of
24 clade B transmitted/founder Envs with that of 17 chronic controls. To increase the
likelihood of an intact mucosal barrier in the acutely infected recipients and thus the
likelihood of identifying phenotypic properties associated with mucosal transmission, only
transmitted/founder Envs from individuals productively infected by a single virus were
enrolled in the acute infection arm of the study. Env pseudotyping was used to assess
envelope function in single-round infectivity assays to compare coreceptor tropism, CCR5
23
utilization, primary CD4+ T-cell subset tropism, dendritic cell trans-infection, Env fusion
kinetics, and neutralization sensitivity between acute and chronic Envs. Transmitted/founder
and chronic Envs were phenotypically equivalent in most assays, although
transmitted/founder Envs were slightly more sensitive to neutralization by the CD4-binding-
site antibodies b12 and VRC01 and by pooled human HIV hyperimmune immunoglobulin
(HIVIG). These findings were independently validated using a panel of 14 additional chronic
HIV-1 Env controls.
With a relatively large number of transmitted/founder and acute Envs now having been
examined across a number of different studies and by different investigative groups, it seems
that no single major genetic or phenotypic signature is required for transmission beyond the
use of CCR5. Current data suggest that an array of genetic traits, including but not limited to
shorter variable loops and reduced numbers of amino-linked glycosylation sites is associated
with enhanced virus transmission at least for subtypes A, C, and possibly B. The structural
implications of these signatures and of the modestly enhanced neutralization sensitivity of
subtype B viruses are not yet understood. However, the possibility exists that relatively subtle
alterations of Env structure and function in the context of the native Env trimer could provide
sufficient selective advantage during the eclipse phase of HIV-1 transmission to result in
preferential transmission of such viruses. The recent finding that HIV-1 gp120 binds to the
CD4+ T-cell gut homing integrin α4β7 has raised the possibility that this capacity is important
to an infecting virus by targeting cells capable of trafficking to the gut-associated lymphoid
tissue (Arthos et al. 2008). It has been reported that α4β7 highly expressing CD4 + T cells are
more susceptible to productive infection by HIV-1 than those expressing low levels of the
integrin, in part because this subset is enriched for activated CD4 + cells, and in part because
α4β7hi cells express high levels of CCR5 and low levels of CXCR4 (Cicala et al. 2009).
Interestingly, a small sample of acute subtype A and C virus Envs bound α4β7 with high
affinity, and in some cases, later virus strains showed significantly reduced binding (Nawaz et
al. 2011), consistent with an early requirement for infection of α4β7-expressing cells that is
dispensable once infection in the gut mucosa has been established. Given that HIV-1
transmission is inherently inefficient and likely represents the most vulnerable point in the
natural history of HIV-1 infection, identifying unique properties and potential vulnerabilities
of transmitted/founder viruses remains an important objective.
24
Figure 3.
Model of cervicovaginal infection by HIV-1. Preferential R5 HIV-1 transmission is illustrated
along with potential roles for Langerhans cells, dendritic cells, and tissue macrophages. Most
HIV-1 transmitted/founder viruses replicate efficiently in CD4 + T cells but not in monocyte-
derived macrophages (Salazar-Gonzalez et al. 2009; Li et al. 2010), raising questions about
the role of macrophages in HIV-1 transmission. Virus-host cell interactions in the initial days
of infection have been elucidated primarily in the SIV-Indian rhesus macaque infection model
(Haase 2010) and in human tissue explants (Hladik and McElrath 2008). (Adapted from Pope
and Haase 2003.)
Mathematical Models
Central to the development and validation of a strategy to identify transmitted/founder virus
genomes by SGA, direct amplicon sequencing, and phylogenetic analysis was the
development of a mathematical model to describe early virus replication and diversification.
This model was developed and refined by Korber, Perelson, and colleagues (Keele et al.
2008; Lee et al. 2009) and used previously estimated parameters of HIV-1 generation time (2
d), reproductive ratio (Ro = 6), and reverse transcriptase error rate (2.16 × 10−5) and assumed
that initial virus replicates exponentially infecting Ro new cells at each generation and
diversifying under a model of evolution that assumes no selection. Viruses were predicted to
show a Poisson distribution of mutations and a star-like phylogeny. This model led Keele and
colleagues (2008) to posit that the progeny of individual transmitted/founder viruses that
25
establish productive clinical infection could thus be identified in acute infection as distinct
low-diversity genetic lineages and that the consensus sequence, or coalescent, of each lineage
would correspond to actual transmitted/founder viruses. These hypotheses were proven to be
valid in both acute HIV-1 and SIV infection (Keele et al. 2008, 2009; Li et al. 2010; Liu et al.
2010; Stone et al. 2010). More recently, Perelson and coworkers developed a stochastic
model of the early HIV-1 infection (Pearson et al. 2011), as opposed to deterministic models,
to probe the earliest virus-host events following virus inoculation. They distinguish virus that
is released from cells continuously versus in a burst and show that these different
mechanisms of virus production lead to substantially different early viral dynamics and
different probabilities of virus extinction. The stochastic model moves us a step closer to
what is believed to be the most vulnerable point in HIV-1 infection, in the hours and days
immediately following virus exposure, and provides insights relevant to vaccine and
therapeutic interventions at this critical period in the transmission process of HIV-1.
26
productive clinical infection in one in every 200–2000 exposed women, and then by a single
virion in 80% of cases (Table 1) (Keele et al. 2008; Abrahams et al. 2009; Haaland et al.
2009). Thus, it is unclear at the present time how closely the in situ virus-host interactions
described thus far for the earliest phases of SIV infection of macaques (Haase 2010)
correspond to eclipse phase events in human HIV-1 infection. Beyond these earliest events,
SIV generally becomes detectable in the blood by the second week of infection and increases
exponentially at a rate comparable or even faster than that of HIV-1 in humans (Lifson et al.
1997; Nowak et al. 1997; Ribeiro et al. 2010).
SIV and HIV-1 presumably invade the new host where mucosal surfaces can most easily be
breached, and for HIV-1 this can be aided by microabrasions caused by the trauma of sexual
intercourse or associated with sexually transmitted diseases or genital ulcerative disease
(Abrahams et al. 2009; Haaland et al. 2009). It is of note that hepatitis C virus (HCV)
generally circulates at even higher titers in human plasma than does HIV-1, yet it is
exceedingly rare for it to be transmitted by penile-vaginal intercourse—so rare that the U.S.
Department of Health and Human Services and Centers for Disease Control do not
recommend barrier protection (condoms) to prevent heterosexual transmission of HCV in
discordant couples. This suggests that the mechanism of transmission of HIV-1 across the
vaginal and cervical mucosa is fundamentally different from a simple exchange of virus-
contaminated blood or blood plasma across an abraded or otherwise traumatized mucosal
surface. A single layer of columnar epithelium covers the endocervix and part of the
transformation zone between endocervix and ectocervix. The endocervix and transformation
zone appear to be preferential but not exclusive sites of HIV-1 entry and early replication (Li
et al. 2009a). The stratified squamous epithelium of the vagina contains Langerhans cells
whose extensions may reach the luminal surface. Langerhans cells are infectable by HIV-1
and can traffic to the submucosa. The submucosa of both the vagina and cervix contain
dendritic cells, which also can become infected or transmit HIV-1 to CD4+ T cells (Boggiano
and Littman 2007; Boggiano et al. 2007; Hladik et al. 2007).
In macaques, the earliest focal collections of productively infected cells in cervical mucosa
and submucosa are CD4+ T cells that show a largely “resting” phenotype and low-level CCR5
expression (Zhang et al. 1999, 2004; Li et al. 2005b). In acute HIV-1 infection of humans,
“resting” CD4+ T cells also play a substantial role in supporting high-level virus replication
(Zhang et al. 1999; Schacker et al. 2001). It is believed that such cells are memory CD4 + T
cells that have reverted to a largely resting phenotype but have retained sufficient CCR5 and
activation pathway molecules to support SIV/HIV replication. This may be accentuated in
GALT, in which α4β7 expression on helper CD17 +/CD4+ T cells may facilitate virus infection
and replication (Arthos et al. 2008; Kader et al. 2009). Interestingly, tissue macrophages are
not a primary target of early SIV infection, consistent with the failure of most
transmitted/founder HIV-1 genomes to replicate efficiently in this cell type in vitro (Salazar-
Gonzalez et al. 2009; Li et al. 2010; C Ochsenbauer, J Kappes, and G Shaw, unpubl.).
Perelson has suggested that mucosal infections by HIV-1, and by analogy SIV, may be
extinguished because of stochastic events in the transmission process (Pearson et al. 2011).
This could be caused by limitations in target cell availability that may be more significant in
cervicovaginal mucosa and submucosa than in rectal tissue (Edwards and Morris 1985; Ma et
al. 2001; Zhang et al. 2004; Pudney et al. 2005; Miyake et al. 2006). A complex interplay of
early innate host defenses may contribute to early virus containment or elimination, but
paradoxically such responses can facilitate transmission by recruiting new potential target
cells for infection (Li et al. 2009a; Haase 2010). Once infection disseminates to locoregional
lymphatics, the GALT, and other secondary lymphoid tissues, massive depletion of memory
27
CD4+ T cells in the lamina propria ensues (Clayton et al. 1997; Veazey et al. 1998; Guadalupe
et al. 2003; Brenchley et al. 2004; Mehandru et al. 2004; Mattapallil et al. 2005; Li et al.
2005b). Massive immune activation, further loss of CD4+ T cells, and an acute enteropathy
commonly follow (Kotler et al. 1984; Heise et al. 1994; Li et al. 2008). Defining critical steps
in the mucosal transmission of SIV and HIV-1, including those most vulnerable to therapeutic
or immunologic modulation or intervention, remains a high priority. Modulation of immune
activation in the SIV–rhesus macaque infection model by glycerol monolaurate represents
proof-of-concept of such an approach to prevention (Li et al. 2009a). Passive immunization
with neutralizing monoclonal antibodies including 2F5, 4E10, 2G12, and B12 in a SHIV
infection model provides another important proof-of-concept of the vulnerability of HIV-1 at
this critical juncture (Mascola 2002; Hessell et al. 2007, 2009a,b).
28
colleagues (Greenhead et al. 2000). This work characterized cellular factors involved in HIV-
1 entry (Hu et al. 2004) and identified potential therapeutic agents that block infection
(Fletcher et al. 2005; Cummins et al. 2007; Buffa et al. 2009). In this model, blockade of CD4
or CCR5/CXCR4 prevented localized mucosal infection and trafficking by dendritic cells.
An extensive ex vivo tissue explant literature thus describes virus-host cell interactions in
female and male genital mucosa that may contribute to natural HIV-1 transmission. This work
includes descriptions of cell targets, cell surface molecules that mediate virus attachment or
infection, and cell signaling pathways that facilitate virus infection and transmission (Hladik
and McElrath 2008). However, a key question still unanswered by in vitro cell culture
analyses, ex vivo tissue explant studies, or in vivo SIV-macaque infection studies is what is
the contribution of Langerhans cells, dendritic cells, or macrophages, compared with
CD4+CCR5+ T cells alone to mucosal transmission of HIV-1 (Fig. 3). As this question is
revisited, attention to the biological relevance and authenticity of the challenge viruses used
in the model systems is warranted. The macrophage-tropic HIV-1 BaL, ADA, and YU2
strains, and the T-cell line-adapted NL4.3 and HXB-2 strains, have been used extensively in
previous transmission model studies, yet none of these viruses appears to faithfully reflect the
properties described thus far for transmitted/founder viruses from acutely infected humans
(Keele et al. 2008; Salazar-Gonzalez et al. 2009; Li et al. 2010; Wilen et al. 2011a). Future
mucosal transmission studies may benefit from using virus challenge strains that more closely
reflect actual transmitted/founder viruses.
CONCLUSIONS
Interrupting HIV-1 transmission by vaccination, microbicides, pre- or postexposure antiviral
drug prophylaxis, or by any of a number of other prevention strategies is of paramount
importance in curbing the HIV/AIDS pandemic. Elucidation of molecular viral-host
interactions responsible for virus transmission and productive clinical infection can be
instrumental in achieving this end. A new strategy for the molecular identification of
transmitted/founder HIV-1 genomes, together with improved tissue explant and in vivo
models of HIV-1 transmission, brings the possibility of elucidating critical HIV-1
transmission events and vulnerabilities within reach. Future studies can benefit from building
on what has become an increasingly firm foundation in our knowledge of HIV-1
transmission.
Footnotes
REFERENCES
*Reference is also in this collection.
Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS,
Treurnicht FK, Keele BF, Wood N, et al. 2009. Quantitating the multiplicity of infection with
human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of
transmitted variants. J Virol 83: 3556–3567 [PMC free article] [PubMed] [Google Scholar]
Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E 2010. Donor and
recipient envs from heterosexual human immunodeficiency virus subtype C transmission
29
pairs require high receptor levels for entry. J Virol 84: 4100–4104 [PMC free
article] [PubMed] [Google Scholar]
Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD,
Conrad TP, Lempicki RA, et al. 2008. HIV-1 envelope protein binds to and signals through
integrin α4β7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9: 301–
309 [PubMed] [Google Scholar]
Asmal M, Hellmann I, Liu W, Keele BF, Perelson AS, Bhattacharya T, Gnanakaran S,
Daniels M, Haynes BF, Korber BT 2011. A signature in HIV-1 envelope leader peptide
associated with transition from acute to chronic infection impacts envelope processing and
infectivity. PLoS One 6: e23673. [PMC free article] [PubMed] [Google Scholar]
Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A 2005. Randomized,
controlled intervention trial of male circumcision for reduction of HIV infection risk: The
ANRS 1265 trial. PLoS Med2: e298. [PMC free article] [PubMed] [Google Scholar]
Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT,
Ndinya-Achola JO 2007. Male circumcision for HIV prevention in young men in Kisumu,
Kenya: A randomised controlled trial. Lancet 369: 643–656 [PubMed] [Google Scholar]
Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun C, Wang S, Learn GH,
Morgan CJ, et al. 2010. Wide variation in the multiplicity of HIV-1 infection among injection
drug users. J Virol 84: 6241–6247 [PMC free article] [PubMed] [Google Scholar]
Berger EA, Murphy PM, Farber JM 1999. Chemokine receptors as HIV-1 coreceptors: Roles
in viral entry, tropism, and disease. Annu Rev Immunol 17: 657–700 [PubMed] [Google
Scholar]
Boggiano C, Littman DR 2007. HIV’s vagina travelogue. Immunity 26: 145–147
[PubMed] [Google Scholar]
Boggiano C, Manel N, Littman DR 2007. Dendritic cell-mediated trans-enhancement of
human immunodeficiency virus type 1 infectivity is independent of DC-SIGN. J Virol 81:
2519–2523 [PMC free article] [PubMed] [Google Scholar]
Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M
2009. Heterosexual risk of HIV-1 infection per sexual act: Systematic review and meta-
analysis of observational studies. Lancet Infect Dis 9: 118–129 [PMC free
article] [PubMed] [Google Scholar]
Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL,
Khoruts A, Larson M, Haase AT, et al. 2004. CD4+ T cell depletion during all stages of HIV
disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749–759 [PMC
free article] [PubMed] [Google Scholar]
Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R,
Rouleau D, Bruneau J, et al. 2007. High rates of forward transmission events after acute/early
HIV-1 infection. J Infect Dis 195: 951–959 [PubMed] [Google Scholar]
30
Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ 2009. Cyanovirin-N potently
inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant
models. J Gen Virol 90: 234–243 [PubMed] [Google Scholar]
Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J
2005. Selection for human immunodeficiency virus type 1 envelope glycosylation variants
with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes
and may impact viral RNA levels. J Virol 79: 6528–6531 [PMC free
article] [PubMed] [Google Scholar]
Church JD, Huang W, Mwatha A, Musoke P, Jackson JB, Bagenda D, Omer SB, Donnell D,
Nakabiito C, Eure C, et al. 2010. Analysis of HIV tropism in Ugandan infants. Curr HIV
Res 8: 498–503 [PMC free article] [PubMed] [Google Scholar]
Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S,
Macleod K, O’Shea A, et al. 2009. The integrin α4β7 forms a complex with cell-surface CD4
and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad
Sci 106: 20877–20882 [PMC free article] [PubMed] [Google Scholar]
Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC,
Hahn BH, Shaw GM 1991. High titers of cytopathic virus in plasma of patients with
symptomatic primary HIV-1 infection. N Engl J Med 324: 954–960 [PubMed] [Google
Scholar]
Clayton F, Snow G, Reka S, Kotler DP 1997. Selective depletion of rectal lamina propria
rather than lymphoid aggregate CD4 lymphocytes in HIV infection. Clin Exp Immunol 107:
288–292 [PMC free article] [PubMed] [Google Scholar]
Cohen MS, Shaw GM, McMichael AJ, Haynes BF 2011a. Acute HIV-1 infection—basic,
clinical, and public health perspectives. N Engl J Med 364: 1943–1954 [PMC free
article] [PubMed] [Google Scholar]
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim
JG, Kumwenda J, Grinsztejn B, Pilotto JHS 2011b. Prevention of HIV-1 infection with early
antiretroviral therapy. N Engl J Med 365: 493–505 [PMC free article] [PubMed] [Google
Scholar]
Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P 2000. Development of an in vitro
organ culture model to study transmission of HIV-1 in the female genital tract. Nat Med 6:
475–479 [PubMed] [Google Scholar]
Cummins JE Jr, Guarner J, Flowers L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA,
Paxton L, Dezzutti CS 2007. Preclinical testing of candidate topical microbicides for anti-
human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant
culture. Antimicrob Agents Chemother51: 1770–1779 [PMC free article] [PubMed] [Google
Scholar]
Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D,
Babiel R, Glaubitz J, Chaix ML, et al. 2010. Evaluation of an upgraded version of the Roche
Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin
Microbiol 48: 1413–1416 [PMC free article] [PubMed] [Google Scholar]
31
Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, Denham SA, Heil ML,
Kasolo F, Musonda R, Hahn BH, et al. 2004. Envelope-constrained neutralization-sensitive
HIV-1 after heterosexual transmission. Science 303: 2019–2022 [PubMed] [Google Scholar]
Dinh MH, Fahrbach KM, Hope TJ 2011. The role of the foreskin in male circumcision: An
evidence-based review. Am J Reprod Immunol 65: 279–283 [PMC free
article] [PubMed] [Google Scholar]
Dunkle KL, Stephenson R, Karita E, Chomba E, Kayitenkore K, Vwalika C, Greenberg L,
Allen S 2008.New heterosexually transmitted HIV infections in married or cohabiting
couples in urban Zambia and Rwanda: An analysis of survey and clinical data. Lancet 371:
2183–2191 [PubMed] [Google Scholar]
Edwards JN, Morris HB 1985. Langerhans’ cells and lymphocyte subsets in the female
genital tract. Br J Obstet Gynaecol 92: 974–982 [PubMed] [Google Scholar]
El-Sadr WM, Mayer KH, Hodder SL 2010. AIDS in America–forgotten but not gone. N Engl
J Med 362: 967–970 [PMC free article] [PubMed] [Google Scholar]
Eshleman SH, Khaki L, Laeyendecker O, Piwowar-Manning E, Johnson-Lewis L, Husnik M,
Koblin B, Coates T, Chesney M, Vallari A, et al. 2009. Detection of individuals with acute
HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic
Syndr 52: 121–124 [PMC free article] [PubMed] [Google Scholar]
Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, Mulenga J, Kasolo F,
Vermund SH, Aldrovandi GM 2001. Virologic and immunologic determinants of
heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res
Hum Retroviruses 17: 901–910 [PMC free article] [PubMed] [Google Scholar]
Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C,
Smith R, Conrad A, Kleinman SH, et al. 2003. Dynamics of HIV viremia and antibody
seroconversion in plasma donors: Implications for diagnosis and staging of primary HIV
infection. AIDS 17: 1871–1879 [PubMed] [Google Scholar]
Fischer W, Ganusov VV, Giorgi EE, Hraber PT, Keele BF, Leitner T, Han CS, Gleasner CD,
Green L, Lo CC, et al. 2010. Transmission of single HIV-1 genomes and dynamics of early
immune escape revealed by ultra-deep sequencing. PLoS One 5: e12303. [PMC free
article] [PubMed] [Google Scholar]
Fischetti L, Barry SM, Hope TJ, Shattock RJ 2009. HIV-1 infection of human penile explant
tissue and protection by candidate microbicides. AIDS 23: 319–328 [PMC free
article] [PubMed] [Google Scholar]
Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R 2005. The
nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus
type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol 79:
11179–11186 [PMC free article] [PubMed] [Google Scholar]
Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ 2006. Ex
vivo culture of human colorectal tissue for the evaluation of candidate
microbicides. AIDS 20: 1237–1245 [PubMed] [Google Scholar]
32
Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, Little SJ, Richman DD
2005.Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation
and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol 79:
6523–6527 [PMC free article] [PubMed] [Google Scholar]
Gaines H, von Sydow M, Pehrson PO, Lundbegh P 1988. Clinical picture of primary HIV
infection presenting as a glandular-fever-like illness. BMJ 297: 1363–1368 [PMC free
article] [PubMed] [Google Scholar]
Galvin SR, Cohen MS 2004. The role of sexually transmitted diseases in HIV
transmission. Nat Rev Microbiol 2: 33–42 [PubMed] [Google Scholar]
Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M 2007. The
emergence of HIV/AIDS in the Americas and beyond. Proc Natl Acad Sci 104: 18566–
18570 [PMC free article] [PubMed] [Google Scholar]
Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, Shen T,
Gaschen B, Krishnamoorthy M, Li H, Decker JM 2011. Recurrent signature patterns in HIV-
1 B clade envelope glycoproteins associated with either early or chronic infections. PloS
Pathog 7: e1002209. [PMC free article] [PubMed] [Google Scholar]
Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F,
Lutalo T, Li X, vanCott T, Quinn TC 2001. Probability of HIV-1 transmission per coital act in
monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357: 1149–
1153 [PubMed] [Google Scholar]
Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, Nalugoda F,
Kiddugavu M, Sewankambo N, Quinn TC, et al. 2005. Increased risk of incident HIV during
pregnancy in Rakai, Uganda: A prospective study. Lancet 366: 1182–1188 [PubMed] [Google
Scholar]
Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton
LH, Chaudhary MA, Chen MZ, et al. 2007. Male circumcision for HIV prevention in men in
Rakai, Uganda: A randomised trial. Lancet 369: 657–666 [PubMed] [Google Scholar]
Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ 2000. Parameters of
human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal
virucides. J Virol 74: 5577–5586 [PMC free article] [PubMed] [Google Scholar]
Grivel JC, Elliott J, Lisco A, Biancoto A, Condack C, Shattock RJ, McGowan I, Margolis L,
Anton P 2007.HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex
vivo with CCR5- and CXCR4-tropic HIV-1. AIDS 21: 1263–1272 [PubMed] [Google
Scholar]
Grobler J, Gray CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA, Morris L, Williamson
C 2004.Incidence of HIV-1 dual infection and its association with increased viral load set
point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 190: 1355–
1359 [PubMed] [Google Scholar]
Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S
2003. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human
immunodeficiency virus type 1 infection and substantial delay in restoration following highly
33
active antiretroviral therapy. J Virol 77: 11708–11717 [PMC free article] [PubMed] [Google
Scholar]
Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O,
Mulenga J, Keele BF, Shaw GM, et al. 2009. Inflammatory genital infections mitigate a
severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS
Pathog 5: e1000274. [PMC free article] [PubMed] [Google Scholar]
Haase AT 2010. Targeting early infection to prevent HIV-1 mucosal
transmission. Nature 464: 217–223 [PubMed] [Google Scholar]
Heise C, Miller CJ, Lackner A, Dandekar S 1994. Primary acute simian immunodeficiency
virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction. J
Infect Dis 169: 1116–1120 [PubMed] [Google Scholar]
Hemelaar J, Gouws E, Ghys PD, Osmanov S 2006. Global and regional distribution of HIV-1
genetic subtypes and recombinants in 2004. AIDS 20: W13–W23 [PubMed] [Google
Scholar]
Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM,
Landucci G, Forthal DN, Parren PW, et al. 2007. Fc receptor but not complement binding is
important in antibody protection against HIV. Nature 449: 101–104 [PubMed] [Google
Scholar]
Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK Parren PW, Marx
PA, Burton DR 2009a. Effective, low-titer antibody protection against low-dose repeated
mucosal SHIV challenge in macaques. Nat Med 15: 951–954 [PMC free
article] [PubMed] [Google Scholar]
Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC,
Watkins DI, Burton DR 2009b. Broadly neutralizing human anti-HIV antibody 2G12 is
effective in protection against mucosal SHIV challenge even at low serum neutralizing
titers. PLoS Pathog 5: e1000433. [PMC free article] [PubMed] [Google Scholar]
Hladik F, McElrath MJ 2008. Setting the stage: Host invasion by HIV. Nat Rev Immunol 8:
447–457 [PMC free article] [PubMed] [Google Scholar]
Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ
2007. Initial events in establishing vaginal entry and infection by human immunodeficiency
virus type-1. Immunity 26: 257–270 [PMC free article] [PubMed] [Google Scholar]
Hu J, Gardner MB, Miller CJ 2000. Simian immunodeficiency virus rapidly penetrates the
cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic
cells. J Virol 74: 6087–6095 [PMC free article] [PubMed] [Google Scholar]
Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Pope M, Shattock RJ
2004. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human
cervical tissue. J Exp Med 199: 1065–1075 [PMC free article] [PubMed] [Google Scholar]
Hudgens MG, Longini IM Jr, Vanichseni S, Hu DJ, Kitayaporn D, Mock PA, Halloran ME,
Satten GA, Choopanya K, Mastro TD 2002. Subtype-specific transmission probabilities for
34
human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am
J Epidemiol 155: 159–168 [PubMed] [Google Scholar]
Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn
CA, Collman RG 2009. Heterosexual transmission of human immunodeficiency virus type 1
subtype C: Macrophage tropism, alternative coreceptor use, and the molecular anatomy of
CCR5 utilization. J Virol 83: 8208–8220 [PMC free article] [PubMed] [Google Scholar]
Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S,
Shankarappa R, Margolick JB, Mullins JI 2003. Improved coreceptor usage prediction and
genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency
virus type 1 env V3 loop sequences. J Virol 77: 13376–13388 [PMC free
article] [PubMed] [Google Scholar]
Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, Mattapallil JJ
2009. α4+β7(hi)CD4+ memory T cells harbor most Th-17 cells and are preferentially infected
during acute SIV infection. Mucosal Immunol2: 439–449 [PMC free
article] [PubMed] [Google Scholar]
Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM,
Palmer S 2009.Human immunodeficiency virus type 1 population genetics and adaptation in
newly infected individuals. J Virol 83: 2715–2727 [PMC free article] [PubMed] [Google
Scholar]
Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C,
Grayson T, Wang S, Li H, et al. 2008. Identification and characterization of transmitted and
early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci 105: 7552–
7557 [PMC free article] [PubMed] [Google Scholar]
Keele BF, Li H, Learn GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW, Letvin
NL, et al. 2009. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or
SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 206: 1117–
1134 [PMC free article] [PubMed] [Google Scholar]
Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S,
Bhattacharya T 2000.Timing the ancestor of the HIV-1 pandemic strains. Science 288: 1789–
1796 [PubMed] [Google Scholar]
Kotler DP, Gaetz HP, Lange M, Klein EB, Holt PR 1984. Enteropathy associated with the
acquired immunodeficiency syndrome. Ann Intern Med 101: 421–428 [PubMed] [Google
Scholar]
Kouyos RD, von Wyl V, Yerly S, Boni J, Taffe P, Shah C, Burgisser P, Klimkait T, Weber R,
Hirschel B, et al. 2010. Molecular epidemiology reveals long-term changes in HIV type 1
subtype B transmission in Switzerland. J Infect Dis 201: 1488–1497 [PubMed] [Google
Scholar]
Learn GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, Corey L 2002. Virus population
homogenization following acute human immunodeficiency virus type 1 infection. J Virol 76:
11953–11959 [PMC free article] [PubMed] [Google Scholar]
35
Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, Pham KT,
Goepfert PA, Kilby JM, Saag MS, et al. 2009. Modeling sequence evolution in acute HIV-1
infection. J Theor Biol 261: 341–360 [PMC free article] [PubMed] [Google Scholar]
Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P,
Gilbert P, Greene KM, et al. 2005a. Human immunodeficiency virus type 1 env clones from
acute and early subtype B infections for standardized assessments of vaccine-elicited
neutralizing antibodies. J Virol 79: 10108–10125 [PMC free article] [PubMed] [Google
Scholar]
Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT
2005b. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria
CD4+ T cells. Nature 434: 1148–1152 [PubMed] [Google Scholar]
Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM,
Li Y, Salazar MG, Polonis VR, et al. 2006. Genetic and neutralization properties of subtype C
human immunodeficiency virus type 1 molecular env clones from acute and early
heterosexually acquired infections in Southern Africa. J Virol 80: 11776–11790 [PMC free
article] [PubMed] [Google Scholar]
Li Q, Estes JD, Duan L, Jessurun J, Pambuccian S, Forster C, Wietgrefe S, Zupancic M,
Schacker T, Reilly C, et al. 2008. Simian immunodeficiency virus-induced intestinal cell
apoptosis is the underlying mechanism of the regenerative enteropathy of early infection. J
Infect Dis 197: 420–429 [PubMed] [Google Scholar]
Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ, Reilly CS, Peterson ML,
Schultz-Darken N, Brunner KG, et al. 2009a. Glycerol monolaurate prevents mucosal SIV
transmission. Nature 458: 1034–1038 [PMC free article] [PubMed] [Google Scholar]
Li Q, Smith AJ, Schacker TW, Carlis JV, Duan L, Reilly CS, Haase AT 2009b. Microarray
analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1
infection. J Immunol 183: 1975–1982 [PMC free article] [PubMed] [Google Scholar]
Li H, Bar KJ, Wang S, Decker JM, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Learn
GH, Morgan CJ, et al. 2010. High multiplicity infection by HIV-1 in men who have sex with
men. PLoS Pathog 6: e1000890. [PMC free article] [PubMed] [Google Scholar]
Lifson JD, Nowak MA, Goldstein S, Rossio JL, Kinter A, Vasquez G, Wiltrout TA, Brown C,
Schneider D, Wahl L, et al. 1997. The extent of early viral replication is a critical determinant
of the natural history of simian immunodeficiency virus infection. J Virol 71: 9508–
9514 [PMC free article] [PubMed] [Google Scholar]
Lindback S, Karlsson AC, Mittler J, Blaxhult A, Carlsson M, Briheim G, Sonnerborg A,
Gaines H 2000a.Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary
HIV Infection Study Group. AIDS14: 2283–2291 [PubMed] [Google Scholar]
Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, Blaxhult A,
Sonnerborg A, Biberfeld G, Gaines H 2000b. Diagnosis of primary HIV-1 infection and
duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study
Group. AIDS 14: 2333–2339 [PubMed] [Google Scholar]
36
Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV 1999. Viral dynamics of acute
HIV-1 infection. J Exp Med 190: 841–850 [PMC free article] [PubMed] [Google Scholar]
Liu J, Keele BF, Li H, Keating S, Norris PJ, Carville A, Mansfield KG, Tomaras GD, Haynes
BF, Kolodkin-Gal D, et al. 2010. Low-dose mucosal simian immunodeficiency virus
infection restricts early replication kinetics and transmitted virus variants in rhesus
monkeys. J Virol 84: 10406–10412 [PMC free article] [PubMed] [Google Scholar]
Long EM, Martin HL Jr, Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ, Rakwar J,
Mandaliya K, Overbaugh J 2000. Gender differences in HIV-1 diversity at time of
infection. Nat Med 6: 71–75 [PubMed] [Google Scholar]
Ma Z, Lu FX, Torten M, Miller CJ 2001. The number and distribution of immune cells in the
cervicovaginal mucosa remain constant throughout the menstrual cycle of rhesus
macaques. Clin Immunol 100: 240–249 [PubMed] [Google Scholar]
Ma Z-M, Stone M, Piatak M Jr, Schweighardt B, Haigwood NL, Montefiori D, Lifson JD,
Busch MP, Miller CJ 2009. High specific infectivity of plasma virus from the pre-ramp-up
and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 83: 3288–
3297 [PMC free article] [PubMed] [Google Scholar]
Ma Z-M, Keele BF, Qureshi H, Stone M, DeSilva V, Fritts L, Lifson JD, Miller CJ
2011. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a
single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum
Retroviruses 10.1089/aid.2011.0090 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Maher D, Wu X, Schacker T, Horbul J, Southern P 2005. HIV binding, penetration, and
primary infection in human cervicovaginal tissue. Proc Natl Acad Sci 102: 11504–
11509 [PMC free article] [PubMed] [Google Scholar]
* Malim MH, Bieniasz PD 2011. HIV restriction factors and mechanisms of evasion. Cold
Spring Harb Perspect Med 10.1101/cshperspect.a006940 [PMC free article] [PubMed]
[CrossRef] [Google Scholar]
Mascola JR 2002. Passive transfer studies to elucidate the role of antibody-mediated
protection against HIV-1. Vaccine 20: 1922–1925 [PubMed] [Google Scholar]
Masharsky AE, Dukhovlinova EN, Verevochkin SV, Toussova OV, Skochilov RV, Anderson
JA, Hoffman I, Cohen MS, Swanstrom R, Kozlov AP 2010. A substantial transmission
bottleneck among newly and recently HIV-1-infected injection drug users in St Petersburg,
Russia. J Infect Dis 201: 1697–1702 [PubMed] [Google Scholar]
Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M 2005. Massive
infection and loss of memory CD4+ T cells in multiple tissues during acute SIV
infection. Nature 434: 1093–1097 [PubMed] [Google Scholar]
McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter
DK, Hural J, Akondy R, et al. 2008. HIV-1 vaccine-induced immunity in the test-of-concept
step study: A case-cohort analysis. Lancet 372: 1894–1905 [PMC free
article] [PubMed] [Google Scholar]
37
Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz P,
Markowitz M 2004. Primary HIV-1 infection is associated with preferential depletion of
CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761–
770 [PMC free article] [PubMed] [Google Scholar]
Merbah M, Introini A, Fitzgerald W, Grivel JC, Lisco A, Vanpouille C, Margolis L
2011. Cervico-vaginal tissue ex vivo as a model to study early events in HIV-1 infection. Am
J Reprod Immunol 65: 268–278 [PMC free article] [PubMed] [Google Scholar]
Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L,
Duan L, Shore MD, et al. 2005. Propagation and dissemination of infection after vaginal
transmission of simian immunodeficiency virus. J Virol 79: 9217–9227 [PMC free
article] [PubMed] [Google Scholar]
Miller WC, Rosenberg NE, Rutstein SE, Powers KA 2010. Role of acute and early HIV
infection in the sexual transmission of HIV. Curr Opin HIV AIDS 5: 277–282 [PMC free
article] [PubMed] [Google Scholar]
Miyake A, Ibuki K, Enose Y, Suzuki H, Horiuchi R, Motohara M, Saito N, Nakasone T,
Honda M, Watanabe T, et al. 2006. Rapid dissemination of a pathogenic simian/human
immunodeficiency virus to systemic organs and active replication in lymphoid tissues
following intrarectal infection. J Gen Virol 87: 1311–1320 [PubMed] [Google Scholar]
Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, McNally JP, Ogundare O, Pascuccio M,
Patel N, Wei D, et al. 2011. The genotype of early-transmitting HIV gp120s promotes αβ-
reactivity, revealing αβCD4+ T cells as key targets in mucosal transmission. PLoS Pathog 7:
e1001301. [PMC free article] [PubMed] [Google Scholar]
Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J,
Kinter A, Fauci AS, Hirsch VM, et al. 1997. Viral dynamics of primary viremia and
antiretroviral therapy in simian immunodeficiency virus infection. J Virol 71: 7518–
7525 [PMC free article] [PubMed] [Google Scholar]
Nugent CT, Dockter J, Bernardin F, Hecht R, Smith D, Delwart E, Pilcher C, Richman D,
Busch M, Giachetti C 2009. Detection of HIV-1 in alternative specimen types using the
APTIMA HIV-1 RNA Qualitative Assay. J Virol Methods 159: 10–14 [PMC free
article] [PubMed] [Google Scholar]
Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu
S, Metcalf JA, et al. 2003. New real-time reverse transcriptase-initiated PCR assay with
single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin
Microbiol 41: 4531–4536 [PMC free article] [PubMed] [Google Scholar]
Pearson JE, Krapivsky P, Perelson AS 2011. Stochastic theory of early viral infection:
Continuous versus burst production of virions. PLoS Comput Biol 7: e1001058. [PMC free
article] [PubMed] [Google Scholar]
Pope M, Haase AT 2003. Transmission, acute HIV-1 infection and the quest for strategies to
prevent infection. Nat Med 9: 847–852 [PubMed] [Google Scholar]
Poss M, Martin HL, Kreiss JK, Granville L, Chohan B, Nyange P, Mandaliya K, Overbaugh J
1995.Diversity in virus populations from genital secretions and peripheral blood from women
38
recently infected with human immunodeficiency virus type 1. J Virol 69: 8118–8122 [PMC
free article] [PubMed] [Google Scholar]
Powers KA, Poole C, Pettifor AE, Cohen MS 2008. Rethinking the heterosexual infectivity of
HIV-1: A systematic review and meta-analysis. Lancet Infect Dis 8: 553–563 [PMC free
article] [PubMed] [Google Scholar]
Pudney J, Quayle AJ, Anderson DJ 2005. Immunological microenvironments in the human
vagina and cervix: Mediators of cellular immunity are concentrated in the cervical
transformation zone. Biol Reprod 73: 1253–1263 [PubMed] [Google Scholar]
Quinn TC 2007. Circumcision and HIV transmission. Curr Opin Infect Dis 20: 33–38
[PubMed] [Google Scholar]
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan
MO, Lutalo T, Gray RH 2000. Viral load and heterosexual transmission of human
immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921–929
[PubMed] [Google Scholar]
Resch W, Hoffman N, Swanstrom R 2001. Improved success of phenotype prediction of the
human immunodeficiency virus type 1 from envelope variable loop 3 sequence using neural
networks. Virology288: 51–62 [PubMed] [Google Scholar]
Ribeiro RM, Qin L, Chavez LL, Li D, Self SG, Perelson AS 2010. Estimation of the initial
viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol 84:
6096–6102 [PMC free article] [PubMed] [Google Scholar]
Richman DD, Wrin T, Little SJ, Petropoulos CJ 2003. Rapid evolution of the neutralizing
antibody response to HIV type 1 infection. Proc Natl Acad Sci 100: 4144–4149 [PMC free
article] [PubMed] [Google Scholar]
Ridzon R, Gallagher K, Ciesielski C, Ginsberg MB, Robertson BJ, Luo CC, DeMaria A Jr,
1997.Simultaneous transmission of human immunodeficiency virus and hepatitis C virus
from a needle-stick injury. N Engl J Med 336: 919–922 [PubMed] [Google Scholar]
Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, Kitrinos KM, Hicks CB, Eron JJ
Jr, Swanstrom R 2004. Multiple V1/V2 env variants are frequently present during primary
infection with human immunodeficiency virus type 1. J Virol 78: 11208–11218 [PMC free
article] [PubMed] [Google Scholar]
Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, Montefiori DC, Meshnick SR,
Swanstrom R 2011.The genetic bottleneck in vertical transmission of subtype C HIV-1 is not
driven by selection of especially neutralization-resistant virus from the maternal viral
population. J Virol 85: 8253–8262 [PMC free article] [PubMed] [Google Scholar]
Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, Lisco A 2010. HIV-
1 sexual transmission: Early events of HIV-1 infection of human cervico-vaginal tissue in an
optimized ex vivo model. Mucosal Immunol 3: 280–290 [PMC free
article] [PubMed] [Google Scholar]
Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, Katabira E,
Ronald A, Clifford DB, Laeyendecker O, et al. 2009. HIV subtype D is associated with
39
dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive
impairment in Kampala, Uganda. Clin Infect Dis 49: 780–786 [PMC free
article] [PubMed] [Google Scholar]
Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES, Overbaugh J
2004. Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not
restricted to certain risk groups or specific HIV-1 subtypes. J Virol 78: 7279–7283 [PMC free
article] [PubMed] [Google Scholar]
Sagar M, Laeyendecker O, Lee S, Gamiel J, Wawer MJ, Gray RH, Serwadda D,
Sewankambo NK, Shepherd JC, Toma J, et al. 2009. Selection of HIV variants with signature
genotypic characteristics during heterosexual transmission. J Infect Dis 199: 580–589 [PMC
free article] [PubMed] [Google Scholar]
Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA,
Farmer P, Hunter E, Allen S, et al. 2008. Deciphering human immunodeficiency virus type 1
transmission and early envelope diversification by single-genome amplification and
sequencing. J Virol 82: 3952–3970 [PMC free article] [PubMed] [Google Scholar]
Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang
S, Baalwa J, Kraus MH, et al. 2009. Genetic identity, biological phenotype, and evolutionary
pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 206:
1273–1289 [PMC free article] [PubMed] [Google Scholar]
Schacker T, Collier AC, Hughes J, Shea T, Corey L 1996. Clinical and epidemiologic features
of primary HIV infection. Ann Intern Med 125: 257–264 [PubMed] [Google Scholar]
Schacker T, Little S, Connick E, Gebhard K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong
JK, Schooley RT, et al. 2001. Productive infection of T cells in lymphoid tissues during
primary and early human immunodeficiency virus infection. J Infect Dis 183: 555–562
[PubMed] [Google Scholar]
* Sharp PM, Hahn BH 2011. Origins of HIV and the AIDS pandemic. Cold Spring Harbor
Perspect Med[PMC free article] [PubMed] [Google Scholar]
Shen R, Richter HE, Clements RH, Novak L, Huff K, Bimczok D, Sankaran-Walters S,
Dandekar S, Clapham PR, Smythies LE, et al. 2009. Macrophages in vaginal but not
intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1
infection. J Virol 83: 3258–3267 [PMC free article] [PubMed] [Google Scholar]
Shen R, Smythies LE, Clements RH, Novak L, Smith PD 2010. Dendritic cells transmit HIV-
1 through human small intestinal mucosa. J Leukoc Biol 87: 663–670 [PMC free
article] [PubMed] [Google Scholar]
Stone M, Keele BF, Ma ZM, Bailes E, Dutra J, Hahn BH, Shaw GM, Miller CJ 2010. A
limited number of simian immunodeficiency virus (SIV) env variants are transmitted to
rhesus macaques vaginally inoculated with SIVmac251. J Virol 84: 7083–7095 [PMC free
article] [PubMed] [Google Scholar]
Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM 2008. The challenge of HIV-1
subtype diversity. N Engl J Med 358: 1590–1602 [PMC free article] [PubMed] [Google
Scholar]
40
UNAIDS 2010. Global Report 2010,
Geneva. http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf
Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M,
Johnson RP, Desrosiers RC, Lackner AA 1998. Gastrointestinal tract as a major site of
CD4+ T cell depletion and viral replication in SIV infection. Science 280: 427–431
[PubMed] [Google Scholar]
Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N,
Kigozi G, Kiddugavu M, Lutalo T, et al. 2005. Rates of HIV-1 transmission per coital act, by
stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 191: 1403–1409 [PubMed] [Google
Scholar]
Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG,
Kilby JM, Saag MS, et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422:
307–312 [PubMed] [Google Scholar]
Wilen CB, Parrish NF, Pfaff JM, Decker JM, Henning EA, Haim H, Sodroski J, Haynes BF,
Montefiori DC, Tilton JC, et al. 2011a. Phenotypic and immunologic comparison of clade B
transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (in press) [PMC free
article] [PubMed] [Google Scholar]
* Wilen CB, Tilton JC, Doms RW 2011b. Cell binding and entry. Cold Spring Harbor
Perspect Med10.1101/cshperspect.a006866 [PMC free article] [PubMed] [CrossRef] [Google
Scholar]
Wira CR, Veronese F 2011. Sexual transmission of HIV in the 21st century. Am J Reprod
Immunol 65: 181–376 [Google Scholar]
Wolfs TF, Zwart G, Bakker M, Goudsmit J 1992. HIV-1 genomic RNA diversification
following sexual and parenteral virus transmission. Virology 189: 103–110
[PubMed] [Google Scholar]
Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, Kunstman KJ,
Furtado MR, Munoz JL 1992. Selective transmission of human immunodeficiency virus type-
1 variants from mothers to infants. Science 255: 1134–1137 [PubMed] [Google Scholar]
Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, Muyembe JJ,
Kabongo JM, Kalengayi RM, Van Marck E, et al. 2008. Direct evidence of extensive
diversity of HIV-1 in Kinshasa by 1960. Nature 455: 661–664 [PMC free
article] [PubMed] [Google Scholar]
Yeh WW, Rao SS, Lim S-Y, Zhang J, Hraber PT, Brassard LM, Luedemann C, Todd JP,
Dodson A, Shen L 2011. The TRIM5 gene modulates penile mucosal acquisition of simian
immunodeficiency virus in Rhesus monkeys. J Virol 85: 10389–10398 [PMC free
article] [PubMed] [Google Scholar]
Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P 1993. Selection for
specific sequences in the external envelope protein of human immunodeficiency virus type 1
upon primary infection. J Virol 67: 3345–3356 [PMC free article] [PubMed] [Google
Scholar]
41
Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA,
Rogan M, Cavert W, Miller CJ, et al. 1999. Sexual transmission and propagation of SIV and
HIV in resting and activated CD4+ T cells. Science 286: 1353–1357 [PubMed] [Google
Scholar]
Zhang ZQ, Wietgrefe SW, Li Q, Shore MD, Duan L, Reilly C, Lifson JD, Haase AT
2004. Roles of substrate availability and infection of resting and activated CD4 + T cells in
transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci 101:
5640–5645 [PMC free article] [PubMed] [Google Scholar]
Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD 1993. Genotypic and phenotypic
characterization of HIV-1 patients with primary infection. Science 261: 1179–1181
[PubMed] [Google Scholar]
Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD 1996. Genetic
characterization of human immunodeficiency virus type 1 in blood and genital secretions:
Evidence for viral compartmentalization and selection during sexual transmission. J Virol 70:
3098–3107 [PMC free article] [PubMed] [Google Scholar]
42
1.2. Jurnal Ver. Terjemahan Indonesia
Penularan HIV
43
dibahas di tempat lain (Malim dan Bieniasz 2011; Sharp dan Hahn 2011). Untuk virus
kelompok M, pemodelan matematika diversifikasi virus menunjukkan leluhur bersama yang
paling baru dekat tahun 1910-1930 (Korber et al. 2000; Worobey et al. 2008), diikuti oleh
penyebaran endemik subklinis virus pada populasi manusia di Afrika Tengah Barat. Di sana,
sebagian besar sebagai akibat dari efek pendiri dan kemacetan populasi virus, HIV-1 muncul
pada akhir 1950-an sebagai subtipe yang secara filogenetik berbeda, di mana sembilan
(subtipe A, B, C, D, F, G, H, J, K) sekarang diakui sebagai penyumbang pandemi global
(Taylor et al. 2008).
Keragaman urutan yang luar biasa di dalam dan di antara subtipe M-1 kelompok HIV-1 yang
berbeda ini, yang dapat mencapai 25% -35% di env, telah memungkinkan pelacakan yang
tepat dari penularan HIV-1 di dalam dan di antara populasi dalam skala global (Gilbert et al.
2007; Taylor et al. 2008) dan antara individu dalam skala mikro (Derdeyn et al. 2004;
Haaland et al. 2009). Sebuah survei global tentang distribusi subtipe HIV-1 dan bentuk-
bentuk rekombinan sirkulasi intersubtipe (CRF) pada tahun 2004 mengungkapkan bahwa
subtipe C menyumbang 50% dari infeksi di seluruh dunia, dengan subtipe A, B, D, dan G
menghasilkan 12%, 10% , 3%, dan 6%, masing-masing, dan subtipe F, H, J, dan K bersama-
sama menyumbang 1% (Hemelaar et al. 2006). Distribusi global dan kompleksitas genetik
subtipe HIV-1 dan CRF terus berkembang (Taylor et al. 2008), dan dengan ini telah muncul
potensi untuk evolusi virus, adaptasi, dan perubahan transmisi. Meskipun lingkungan ini
subur untuk mutasi, ada sedikit bukti untuk perbedaan bermakna antara subtipe HIV-1 dalam
pola atau efisiensi penularannya. Contoh terbaik dari perbedaan dalam probabilitas penularan
adalah untuk CRF01_AE pada pengguna narkoba suntikan (Penasun) di Thailand, yang
meningkat secara substansial dalam prevalensi antara 1995-1998 dibandingkan dengan virus
subtipe B. Namun, tidak jelas apakah faktor epidemiologis, faktor host, atau sifat virus yang
bertanggung jawab (Hudgens et al. 2002). Ada juga pengamatan epidemiologis bahwa virus
subtipe D dari Uganda dan daerah tetangga mungkin menunjukkan tropisme ganda R5 / X4
lebih umum daripada subtipe HIV-1 lainnya, tetapi ini mungkin memiliki efek yang lebih
besar pada patogenesis virus daripada pada penularannya sendiri (Church et al. 2010).
Dengan demikian, tidak seperti virus influenza di mana mutasi genetik yang sedang
berlangsung secara dramatis berdampak pada frekuensi dan pola penularan virus, tidak
demikian halnya dengan pandemi virus HIV-1 kelompok M, yang telah sangat konsisten
dalam hal penularannya dalam rentang waktu, geografi, dan populasi target (Taylor et al.
2008) dan ketika virus berpindah antara individu dan kelompok individu dengan perilaku
risiko dan rute penularan virus yang sangat berbeda (Kouyos et al. 2010).
44
RUTE TRANSMISI DAN RISIKO UNTUK INFEKSI HIV-1
Pada tahun 2009, diperkirakan 2,6 juta orang secara global menjadi baru terinfeksi oleh HIV-
1 (UNAIDS 2010). Ini merupakan pengurangan infeksi baru sebesar 21% dibandingkan
dengan tahun 1997 ketika insiden infeksi memuncak. Tetapi penurunan angka kejadian HIV-1
tidak seragam di semua wilayah dan kelompok risiko, menyoroti pentingnya berbagai rute
penularan dan perilaku berisiko dalam memfasilitasi penularan HIV-1. Contoh paling ekstrem
adalah di Eropa Timur dan Asia Tengah di mana prevalensi HIV-1 meningkat tiga kali lipat
antara 2001-2009 sebagai konsekuensi dari epidemi terkonsentrasi yang terkait dengan kerja
seks, penggunaan narkoba, dan laki-laki yang berhubungan seks dengan laki-laki (LSL)
(UNAIDS 2010). Tabel 1 merangkum risiko penularan HIV-1 terkait dengan berbagai rute
penularan dan kontribusi relatifnya terhadap prevalensi HIV-1 di seluruh dunia. Apa yang
terbukti dari perkiraan ini adalah bahwa penularan heteroseksual bertanggung jawab atas
hampir 70% dari infeksi HIV-1 di seluruh dunia dengan sisanya sebagian besar disebabkan
oleh LSL, infeksi ibu-bayi, dan penggunaan narkoba suntikan. Ini adalah kasus meskipun
fakta bahwa probabilitas penularan per tindakan coital adalah yang terendah untuk paparan
heteroseksual (1 dalam 200-1 dalam 3000) (Hladik dan McElrath 2008; McElrath et al.
2008). Namun, dua meta-analisis baru-baru ini tentang kejadian HIV-1 dan data prevalensi
(Powers et al. 2008; Boily et al. 2009) menunjukkan rentang risiko penularan HIV-1 yang
jauh lebih luas untuk pajanan heteroseksual tergantung pada faktor-faktor risiko perancu
seperti genital penyakit maag, sunat pada pria, stadium penyakit HIV, dan rute paparan.
Sebagai contoh, penularan melalui penis-vaginal dari HIV-1 dilaporkan pada frekuensi
setinggi 1 dari 10 pajanan dan penularan anal-penis setinggi 1 dalam 3 tergantung pada faktor
risiko yang membingungkan (Powers et al. 2008). Dengan demikian, perkiraan risiko yang
umum dikutip untuk akuisisi HIV-1 heteroseksual dari 1 dalam 1000 paparan harus dianggap
sebagai batas bawah
Tabel 1.
Rute penularan dan risiko infeksi HIV-1
45
Lokasi Sublokasi Jenis epitelium Media Peluang Estimasi
Infasi HIV anatomi Transmisi transmisi per kontribusi
kejadian paparan untuk kasus
HIV di seluruh
dunia
Saluran Vagina Squamous, tanpa Air mani;darah 1 dalam 200–1 12.6 juta
genetal lemak dalam 2000
perempuan
Ectocervix Squamous,
nonkeratinized
Endocervix kolom,satu
lapisan
lainnya berbagai
Other Various
46
Lokasi Sublokasi Jenis epitelium Media Peluang Estimasi
Infasi HIV anatomi Transmisi transmisi per kontribusi
kejadian paparan untuk kasus
HIV di seluruh
dunia
Intestinal Rectum Columnar, single Semen; blood 1 in 20–1 in 300 3.9 millionb
tract layer
Diadaptasi dari pembaruan epidemi AIDS UNAIDS / WHO 2010 dan Hladik dan McElrath (2008).
a. Termasuk laki-laki berhubungan seks dengan laki-laki (LSL), laki-laki biseksual, dan laki-laki
heteroseksual.
47
Lokasi Sublokasi Jenis epitelium Media Peluang Estimasi
Infasi HIV anatomi Transmisi transmisi per kontribusi
kejadian paparan untuk kasus
HIV di seluruh
dunia
b. Termasuk LSL, pria biseksual, dan wanita yang terinfeksi melalui hubungan seks anal.
c. Penularan dari ibu ke anak.
d. Sebagian besar penggunaan obat intravena, tetapi termasuk infeksi oleh transfusi dan
kecelakaan yang berhubungan dengan perawatan kesehatan. GI, pencernaan.
Faktor sosial ekonomi juga dapat mempengaruhi penularan HIV-1 secara tidak langsung. El-
Sadr dan rekannya menyarankan bahwa di Amerika Serikat, risiko tertular infeksi HIV-1
lebih ditentukan oleh "jaringan seksual" seseorang daripada oleh perilaku risiko individu,
dengan yang pertama dipengaruhi terutama oleh faktor sosial ekonomi (El-Sadr). et al. 2010).
Pada basis global, estimasi penularan HIV-1 per tindakan coital bervariasi secara signifikan
antara negara-negara berpenghasilan tinggi, di mana estimasi penularan pria ke wanita adalah
0,08% dan tingkat wanita ke pria (FTM) 0,04%, dan negara-negara berpenghasilan rendah ,
di mana tingkat transmisi MTF dan FTM masing-masing adalah 0,38% dan 0,3% (Powers et
al. 2008; Boily et al. 2009). Perbedaan-perbedaan ini sebagian mencerminkan frekuensi
relatif pasangan serodiskordan HIV di dua rangkaian karena telah diperkirakan bahwa mereka
mewakili sumber mayoritas infeksi orang dewasa di banyak negara berpenghasilan rendah
(Dunkle et al. 2008).
Viral load (vL) pada pasangan yang mentransmisikan memainkan peran utama dalam
menentukan risiko penularan HIV-1 dari satu orang ke orang lain. Walaupun vL kemungkinan
mempengaruhi semua mode penularan, hal itu paling baik ditandai pada pasangan sumbang
HIV-1, di mana sebanyak 2,5 kali lipat peningkatan penularan diamati untuk setiap
peningkatan 10 kali lipat dalam vL (Quinn 2000; Fideli et al 2001). Selain itu, meskipun vL
dalam sekresi genital mungkin tidak berkorelasi langsung dengan darah, pasangan dengan vL
plasma kurang dari 1000 jarang ditularkan ke pasangannya (Quinn et al. 2000; Fideli et al.
2001). Pengamatan baru-baru ini (Studi Jaringan Percobaan Pencegahan HIV 052, unpubl.)
Bahwa pengobatan antiretroviral dari pasangan positif dari pasangan yang sumbang dapat
menghasilkan penurunan 96% dalam penularan konsisten dengan temuan ini (Cohen et al.
2011b). Tahap klinis infeksi (akut vs sedang vs terlambat) pada pasangan yang
48
mentransmisikan juga dapat memainkan peran kunci dalam menentukan efisiensi penularan,
dengan risiko infeksi dari orang dengan infeksi akut atau dini lebih tinggi daripada infeksi
pada orang yang sudah terinfeksi. (Wawer et al. 2005; Brenner et al. 2007; Powers et al.
2008; Miller et al. 2010). Ini kemungkinan mencerminkan tingginya vL yang diamati pada
infeksi akut, kurangnya antibodi penawar yang dapat menonaktifkan virus yang bersirkulasi
pada infeksi yang sudah ada, dan amplifikasi klon virus yang sangat fit pada infeksi akut
yang sangat cocok untuk memulai infeksi produktif (Richman et al. 2003; Wei et al. 2003;
Wawer et al. 2005; Keele et al. 2008; Cohen et al. 2011a). Memang, dalam model maca
rhesus India dari penularan SIV, SIV dalam plasma dari hewan pada tahap akut infeksi
memiliki infektivitas spesifik hingga 750 kali lebih besar daripada virus dalam plasma dari
hewan yang terinfeksi secara kronis (Ma et al. 2009 ).
Efisiensi penularan HIV-1 dapat dimodulasi oleh faktor-faktor lain, termasuk penyakit
menular seksual, terutama yang mengakibatkan peradangan genital dan bisul, yang dapat
meningkatkan pelepasan HIV ke dalam saluran genital dan dapat meningkatkan kerentanan
infeksi dua hingga 11- lipatan (Galvin dan Cohen 2004); kehamilan, di mana peningkatan
risiko penularan HIV lebih dari dua kali lipat telah diamati (Gray et al. 2005); dan sunat, yang
dalam serangkaian uji klinis telah terbukti mengurangi risiko penularan penularan pada
pasangan pria sebesar 60% (Auvert et al. 2005; Bailey et al. 2007; Gray et al. 2007; Quinn
2007).
50
Gambar 1.
Pementasan laboratorium dan riwayat alami infeksi HIV-1 akut dan dini. Durasi rata-rata dan
interval kepercayaan 95% (tanda kurung) dari fase gerhana dan tahap Fiebig (Fiebig et al.
2003) dari infeksi akut ditunjukkan pada inset.
Gambar 2.
Model penularan HIV-1. Vrion HIV-1 yang melanggar mukosa mungkin memiliki nasib yang berbeda.
Pengukuran empiris replikasi dan diversifikasi virus, bersama-sama dengan model matematika dari evolusi virus
acak, memungkinkan untuk identifikasi molekuler yang tepat dari virus yang ditransmisikan / pendiri yang
bertanggung jawab untuk infeksi klinis yang produktif (Keele et al. 2008; Lee et al. 2009). R0 adalah rasio
reproduksi. R0> 1 mengarah ke infeksi klinis yang produktif, sedangkan R0 <1 menghasilkan infeksi yang
padam.
Penelitian tambahan tentang kohort manusia yang terinfeksi secara akut menggunakan
sekuensing amplikon SGA-langsung memberikan wawasan lebih lanjut tentang hambatan
55
populasi HIV-1. Studi-studi ini berfokus pada penularan heteroseksual di Afrika sub-Sahara
(Abrahams et al. 2009; Haaland et al. 2009; J Baalwa dan G Shaw, unpubl.), Penularan MSM
di Amerika Serikat (Kearney et al. 2009; Li et al 2010), penularan penggunaan narkoba
suntikan di Kanada, Rusia, dan Thailand (Bar et al. 2010; Masharsky et al. 2010; K Bar dan
G Shaw, unpubl.), Dan yang terbaru, penularan ibu-bayi di Malawi (Russell) et al. 2011).
Masing-masing dari studi ini memberikan identifikasi molekuler gen atau genom virus yang
ditransmisikan / ditemukan dan perkiraan yang tepat dari jumlah virus yang ditransmisikan /
pendiri yang bertanggung jawab atas infeksi klinis yang produktif. Dua penelitian
menggunakan sekuens amplikon langsung-SGA untuk mengidentifikasi genom pendiri
lengkap yang ditransmisikan (Salazar-Gonzalez et al. 2009; Li et al. 2010). Ringkasan dari
semua penelitian ini, yang mencakup lebih dari 300 subyek yang terinfeksi akut,
menunjukkan bahwa sekitar 80% dari subyek heteroseksual secara produktif terinfeksi oleh
genom virus tunggal (Keele dkk. 2008; Abrahams dkk. 2009; Haaland dkk. 2009 ) dan sekitar
60% dan 40% dari LSL dan Penasun, masing-masing, secara produktif terinfeksi oleh genom
tunggal. Kisaran genom yang ditransmisikan / ditemukan yang menghasilkan infeksi klinis
yang produktif dalam studi ini adalah 1–16, dan tidak mengherankan, jumlah tertinggi ada di
penasun (Bar et al. 2010; Li et al. 2010; Masharsky et al. 2010; K Bar dan G Shaw, unpubl.).
Untuk transmisi ibu-bayi, 68% terinfeksi secara produktif oleh virus tunggal dan ini
bervariasi tergantung pada rute transmisi intrauterin versus intrapartum (Russell et al. 2011).
Perbedaan yang diamati dalam multiplisitas infeksi virus yang terkait dengan rute penularan
yang berbeda kira-kira sejajar dengan risiko relatif infeksi klinis berdasarkan setiap kejadian
(Tabel 1). Seperti yang diperkirakan untuk virus yang ditransmisikan / pendiri, gen-gen env
yang ditransmisikan / ditemukan selalu berfungsi secara biologis dan genom berdurasi penuh
selalu kompeten replikasi (Keele dkk. 2008; Salazar-Gonzalez dkk. 2009; Li et al. 2010; C
Ochsenbauer, J Kappes, dan G Shaw, unpubl.). Menariknya, dalam studi penularan
heteroseksual terutama (Keele et al. 2008; Abrahams et al. 2009), pada orang-orang di mana
banyak virus memulai infeksi, jumlah varian yang menginfeksi tidak mengikuti distribusi
Poisson. Temuan ini tidak konsisten dengan setiap varian yang ditransmisikan secara
independen dan dengan probabilitas rendah dan menunjukkan bahwa kofaktor penularan
seperti infeksi menular seksual (IMS) atau kontrasepsi hormonal menurunkan penghalang
penularan (Abrahams et al. 2009; Haaland et al. 2009). Interpretasi ini konsisten dengan
model yang digambarkan pada Gambar 2, di mana penularan virus dapat gagal pada beberapa
langkah setelah inokulasi ke permukaan mukosa. Dengan demikian, IMS termasuk penyakit
ulkus kelamin dapat membatalkan penghalang yang dikenakan oleh mukosa utuh dengan
56
menginduksi kerusakan pada lapisan epitel, sehingga memungkinkan lebih banyak varian
virus untuk memulai infeksi pada jaringan mukosa. Atau, peradangan yang disebabkan oleh
IMS dapat meningkatkan ketersediaan sel CD4 teraktivasi yang diperlukan untuk memulai
infeksi yang menyebar, dengan cara ini memungkinkan infeksi yang akan gagal karena
kurangnya sel target yang tersedia untuk berkembang. Akhirnya, perbandingan SGA baru-
baru ini tentang keragaman genetik HIV dalam saluran genital pasangan yang
mentransmisikan ke virus yang ditransmisikan / pendiri pada pasangan yang terinfeksi akut
berpendapat menentang kompartemen genital varian virus tertentu dalam donor sebagai
bertanggung jawab atas asal-usul hambatan populasi , konsisten dengan model yang disajikan
pada Gambar 2 (D Boeras, dan E Hunter, unpubl.).
Gambar 3.
Model infeksi servikovaginal oleh HIV-1. Penularan HIV-1 R5 preferensial diilustrasikan bersama
dengan peran potensial untuk sel Langerhans, sel dendritik, dan makrofag jaringan. Sebagian besar
virus yang ditularkan / pendiri HIV-1 mereplikasi secara efisien dalam sel T CD4 + tetapi tidak pada
makrofag yang diturunkan monosit (Salazar-Gonzalez dkk. 2009; Li dkk. 2010), menimbulkan
pertanyaan tentang peran makrofag dalam penularan HIV-1. Interaksi sel host-virus pada hari-hari
awal infeksi telah dijelaskan terutama dalam model infeksi kera rhesus India (Haase 2010) dan pada
62
eksplan jaringan manusia (Hladik dan McElrath 2008). (Diadaptasi dari Paus dan Haase 2003.)
Model Matematika
Pusat pengembangan dan validasi strategi untuk mengidentifikasi genom virus yang
ditransmisikan / ditemukan oleh SGA, sekuensing amplikon langsung, dan analisis
filogenetik adalah pengembangan model matematika untuk menggambarkan replikasi dan
diversifikasi virus awal. Model ini dikembangkan dan disempurnakan oleh Korber, Perelson,
dan rekan (Keele dkk. 2008; Lee dkk. 2009) dan menggunakan parameter perkiraan waktu
generasi HIV-1 sebelumnya (2 hari), rasio reproduksi (Ro = 6), dan membalikkan tingkat
kesalahan transkriptase (2,16 × 10−5) dan mengasumsikan bahwa virus awal bereplikasi
secara eksponensial menginfeksi sel-sel baru Ro pada setiap generasi dan melakukan
diversifikasi di bawah model evolusi yang tidak memiliki pilihan. Virus diprediksi
menunjukkan distribusi mutasi Poisson dan filogeni mirip bintang. Model ini membuat Keele
dkk (2008) berpendapat bahwa keturunan dari individu yang ditularkan / virus pendiri yang
menciptakan infeksi klinis yang produktif dapat diidentifikasi dalam infeksi akut sebagai
garis keturunan genetik dengan keragaman rendah dan bahwa urutan konsensus, atau
gabungan, masing-masing garis keturunan akan sesuai dengan virus yang ditransmisikan /
pendiri. Hipotesis ini terbukti valid pada infeksi HIV-1 dan SIV akut (Keele et al. 2008, 2009;
Li et al. 2010; Liu et al. 2010; Stone et al. 2010). Baru-baru ini, Perelson dan rekan kerja
mengembangkan model stokastik dari infeksi HIV-1 awal (Pearson et al. 2011), sebagai
lawan dari model deterministik, untuk menyelidiki kejadian host virus paling awal setelah
inokulasi virus. Mereka membedakan virus yang dilepaskan dari sel secara terus-menerus
versus dalam ledakan dan menunjukkan bahwa mekanisme produksi virus yang berbeda ini
mengarah pada dinamika virus awal yang sangat berbeda dan berbagai kemungkinan
kepunahan virus. Model stokastik menggerakkan kita selangkah lebih dekat ke apa yang
diyakini sebagai titik paling rentan dalam infeksi HIV-1, dalam beberapa jam dan hari segera
setelah paparan virus, dan memberikan wawasan yang relevan dengan vaksin dan intervensi
terapeutik pada periode kritis dalam penularan ini. proses HIV-1.
67
Literatur eksplan jaringan ex vivo yang luas dengan demikian menggambarkan interaksi sel
yang dihosting virus pada mukosa genital perempuan dan laki-laki yang mungkin
berkontribusi pada penularan HIV-1 alami. Karya ini mencakup deskripsi target sel, molekul
permukaan sel yang memediasi perlekatan atau infeksi virus, dan jalur pensinyalan sel yang
memfasilitasi infeksi dan transmisi virus (Hladik dan McElrath 2008). Namun, pertanyaan
kunci masih belum terjawab oleh analisis kultur sel in vitro, studi eksplan jaringan ex vivo,
atau studi infeksi SIV-kera in vivo adalah apa kontribusi sel Langerhans, sel dendritik, atau
makrofag, dibandingkan dengan CD4 + CCR5 + Sel T sendiri untuk transmisi mukosa HIV-1
(Gbr. 3). Ketika pertanyaan ini ditinjau kembali, perhatian terhadap relevansi biologis dan
keaslian virus tantangan yang digunakan dalam sistem model diperlukan. Strain makrofag-
tropik HIV-1 BaL, ADA, dan YU2, dan strain T-cell-line NL4.3 dan HXB-2 yang diadaptasi,
telah digunakan secara luas dalam studi model transmisi sebelumnya, tetapi tidak ada virus
yang tampak setia. mencerminkan sifat yang dijelaskan sejauh ini untuk virus yang
ditransmisikan / ditemukan dari manusia yang terinfeksi secara akut (Keele et al. 2008;
Salazar-Gonzalez et al. 2009; Li et al. 2010; Wilen et al. 2011a). Studi penularan mukosa di
masa depan mungkin mendapat manfaat dari menggunakan strain tantangan virus yang lebih
dekat mencerminkan virus yang ditransmisikan / pendiri.
KESIMPULAN
Menginterupsi penularan HIV-1 dengan vaksinasi, mikrobisida, profilaksis obat antivirus pra
atau pasca pajanan, atau dengan salah satu dari sejumlah strategi pencegahan lainnya adalah
sangat penting dalam mengendalikan pandemi HIV / AIDS. Penjelasan interaksi host-virus
molekuler yang bertanggung jawab untuk penularan virus dan infeksi klinis produktif dapat
berperan dalam mencapai tujuan ini. Strategi baru untuk identifikasi molekuler genom HIV-1
yang ditransmisikan / ditemukan, bersama dengan peningkatan jaringan eksplan dan model
transmisi HIV-1 in vivo, membawa kemungkinan untuk menguraikan peristiwa penularan dan
kerentanan penularan HIV-1 yang kritis dalam jangkauan. Penelitian di masa depan dapat
mengambil manfaat dari membangun apa yang menjadi landasan yang semakin kuat dalam
pengetahuan kita tentang penularan HIV-1.
Catatan kaki
Editor: Frederic D. Bushman, Gary J. Nabel, dan Ronald Swanstrom
Perspektif Tambahan tentang HIV tersedia di www.perspectivesinmedicine.org
68
REFERENSI
* Referensi juga ada di koleksi ini.
Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS,
Treurnicht FK, Keele BF, Wood N, dkk. 2009. Mengukur banyaknya infeksi dengan human
immunodeficiency virus tipe 1 subtipe C mengungkapkan distribusi varian yang
ditransmisikan. J Virol 83: 3556-3567 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Alexander M, Lynch R, Mulenga J, Allen S, Derdeyn CA, Hunter E 2010. Donor dan
penerima envs dari heteroseksual human immunodeficiency virus subtipe C pasangan
transmisi pasangan C memerlukan tingkat reseptor tinggi untuk masuk. J Virol 84: 4100–
4104 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Arthos J, Cicala C, Martinelli E, Macleod K, Van Ryk D, Wei D, Xiao Z, Veenstra TD,
Conrad TP, Lempicki RA, dkk. 2008. Protein amplop HIV-1 berikatan dan memberi sinyal
melalui integrin α4β7, reseptor homing usus mukosa untuk sel T perifer. Nat Immunol 9:
301–309 [PubMed] [Google Cendekia]
Asmal M, Hellmann I, Liu W, Keele BF, Perelson AS, Bhattacharya T, Gnanakaran S,
Daniels M, Haynes BF, Korber BT 2011. Tanda tangan pada pemimpin amplop HIV-1
peptida yang terkait dengan transisi dari amplop dampak infeksi akut ke kronis pemrosesan
dan infektivitas. PLoS One 6: e23673. [Artikel gratis PMC] [PubMed] [Google Cendekia]
Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A 2005. Acak,
percobaan intervensi terkontrol sunat laki-laki untuk mengurangi risiko infeksi HIV: uji coba
ANRS 1265. PLoS Med2: e298. [Artikel gratis PMC] [PubMed] [Google Cendekia]
Bailey RC, Musa S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT,
Ndinya-Achola JO 2007. Sunat laki-laki untuk pencegahan HIV pada laki-laki muda di
Kisumu, Kenya: Sebuah uji coba terkontrol secara acak. Lancet 369: 643–656 [PubMed]
[Google Cendekia]
Bar KJ, Li H, Chamberland A, Tremblay C, Routy JP, Grayson T, Sun C, Wang S, Belajar
GH, Morgan CJ, dkk. 2010. Variasi yang luas dalam multiplisitas infeksi HIV-1 di antara
pengguna narkoba suntikan. J Virol 84: 6241-6247 [Artikel gratis PMC] [PubMed] [Google
Cendekia]
Berger EA, Murphy PM, Farber JM 1999. Reseptor kemokin sebagai koreseptor HIV-1:
Peran dalam entri virus, tropisme, dan penyakit. Annu Rev Immunol 17: 657–700 [PubMed]
[Google Cendekia]
Boggiano C, Littman DR 2007. Perjalanannya melalui vagina. Kekebalan 26: 145–147
[PubMed] [Google Cendekia]
69
Boggiano C, Manel N, Littman DR 2007. Trans-peningkatan yang dimediasi sel denditik dari
human immunodeficiency virus tipe 1 infektivitas tidak tergantung pada DC-SIGN. J Virol
81: 2519–2523 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Boily MC, RF Baggaley, Wang L, Masse B, RG Putih, Hayes RJ, Alary M 2009. Risiko
heteroseksual infeksi HIV-1 per tindakan seksual: Tinjauan sistematis dan meta-analisis dari
studi observasi. Lancet Infect Dis 9: 118-129 [Artikel gratis PMC] [PubMed] [Google
Cendekia]
Brenchley JM, TW Schacker, Ruff LE, Harga DA, Taylor JH, Beilman GJ, Nguyen PL,
Khoruts A, Larson M, Haase AT, dkk. 2004. Penipisan sel T CD4 + selama semua tahap
penyakit HIV terjadi terutama di saluran pencernaan. J Exp Med 200: 749–759 [Artikel gratis
PMC] [PubMed] [Google Cendekia]
Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, Baril JG, Thomas R,
Rouleau D, Bruneau J, dkk. 2007. Tingginya angka kejadian penularan ke depan setelah
infeksi akut / dini HIV-1. J Infect Dis 195: 951–959 [PubMed] [Google Cendekia]
Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ 2009. Cyanovirin-N berpotensi
menghambat infeksi human immunodeficiency virus tipe 1 pada model eksplan seluler dan
serviks. J Gen Virol 90: 234–243 [PubMed] [Google Cendekia]
Chohan B, Lang D, Sagar M, Korber B, Lavreys L, Richardson B, Overbaugh J 2005. Seleksi
untuk varian human immunodeficiency virus tipe 1 amplop glikosilasi dengan urutan loop
V1-V2 yang lebih pendek terjadi selama transmisi subtipe genetik tertentu dan dapat
berdampak pada virus Tingkat RNA. J Virol 79: 6528-6531 [artikel gratis PMC] [PubMed]
[Google Cendekia]
Gereja JD, Huang W, Mwatha A, Musoke P, Jackson JB, Bagenda D, Omer SB, Donnell D,
Nakabiito C, Eure C, dkk. 2010. Analisis tropisme HIV pada bayi Uganda. Curr HIV Res 8:
498-503 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, Jelicic K, Kottilil S,
Macleod K, O'Shea A, dkk. 2009. Integrin α4β7 membentuk kompleks dengan permukaan sel
CD4 dan mendefinisikan subset sel-T yang sangat rentan terhadap infeksi oleh HIV-1. Proc
Natl Acad Sci 106: 20877–20882 [artikel gratis PMC] [PubMed] [Google Cendekia]
Clark SJ, Saag MS, Decker WD, Campbell-Hill S, Roberson JL, Veldkamp PJ, Kappes JC,
Hahn BH, Shaw GM 1991. Titer tinggi virus sitopatik dalam plasma pasien dengan infeksi
primer HIV-1 yang bergejala. N Engl J Med 324: 954–960 [PubMed] [Google Cendekia]
70
Clayton F, Snow G, Reka S, Kotler DP 1997. Penipisan selektif lamina propria selektif
daripada limfosit agregat limfosit CD4 pada infeksi HIV. Clin Exp Immunol 107: 288–292
[artikel gratis PMC] [PubMed] [Google Cendekia]
Cohen MS, Shaw GM, McMichael AJ, Haynes BF 2011a. Infeksi HIV-1 akut — perspektif
dasar, klinis, dan kesehatan masyarakat. N Engl J Med 364: 1943–1954 [artikel gratis PMC]
[PubMed] [Google Cendekia]
Cohen MS, Chen YQ, M McCauley, Gamble T, MC Hosseinipour, Kumarasamy N, Hakim
JG, Kumwenda J, Grinsztejn B, Pilotto JHS 2011b. Pencegahan infeksi HIV-1 dengan terapi
antiretroviral dini. N Engl J Med 365: 493-505 [Artikel gratis PMC] [PubMed] [Google
Cendekia]
Collins KB, Patterson BK, Naus GJ, Landers DV, Gupta P 2000. Pengembangan model kultur
organ in vitro untuk mempelajari transmisi HIV-1 di saluran genital wanita. Nat Med 6: 475–
479 [PubMed] [Google Cendekia]
Cummins JE Jr, Guarner J, Bunga L, Guenthner PC, Bartlett J, Morken T, Grohskopf LA,
Paxton L, Dezzutti CS 2007. Pengujian praklinis kandidat mikrobisida topikal untuk aktivitas
anti-human immunodeficiency virus tipe 1 aktivitas dan toksisitas jaringan pada manusia
budaya eksplan serviks. Agen Antimicrob Chemother51: 1770–1779 [artikel gratis PMC]
[PubMed] [Google Cendekia]
Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D,
Babiel R, Glaubitz J, Chaix ML, dkk. 2010. Evaluasi versi upgrade dari tes HIV-1 Roche
Cobas AmpliPrep / Cobas untuk kuantifikasi beban HIV-1. J Clin Microbiol 48: 1413–1416
[Artikel gratis PMC] [PubMed] [Google Cendekia]
Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, M Muldoon, Denham SA, Heil ML,
Kasolo F, Musonda R, Hahn BH, dkk. 2004. Amplopik yang dibatasi netralisasi-sensitif HIV-
1 setelah penularan heteroseksual. Sains 303: 2019-2022 [PubMed] [Google Cendekia]
Dinh MH, Fahrbach KM, Hope TJ 2011. Peran kulup dalam sunat laki-laki: Sebuah tinjauan
berbasis bukti. Am J Reprod Immunol 65: 279–283 [Artikel gratis PMC] [PubMed] [Google
Cendekia]
Dunkle KL, Stephenson R, E Karita, Chomba E, Kayitenkore K, Vwalika C, Greenberg L,
Allen S 2008.New infeksi HIV yang ditularkan secara heteroseksual pada pasangan menikah
atau tinggal bersama di perkotaan Zambia dan Rwanda: Analisis survei dan data klinis.
Lancet 371: 2183–2191 [PubMed] [Google Cendekia]
Edwards JN, Morris HB 1985. Sel-sel Langerhans dan subset limfosit dalam saluran genital
wanita. Br J Obstet Gynaecol 92: 974–982 [PubMed] [Google Cendekia]
71
El-Sadr WM, Mayer KH, Hodder SL 2010. AIDS di Amerika — dilupakan tetapi tidak
hilang. N Engl J Med 362: 967–970 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Eshleman SH, Khaki L, Laeyendecker O, Piwowar-Manning E, Johnson-Lewis L, Husnik M,
Koblin B, Coates T, Chesney M, Vallari A, et al. 2009. Deteksi individu dengan infeksi HIV-1
akut menggunakan ARCHITECT HIV Ag / Ab Combo assay. J Memperoleh Immune Defic
Syndr 52: 121–124 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Fideli AS, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, Mulenga J, Kasolo F,
Vermund SH, Aldrovandi GM 2001. Penentu virologi dan imunologi dari penularan
heteroseksual dari virus human immunodeficiency type 1 di Afrika. AIDS Res Hum
Retrovirus 17: 901-910 [artikel gratis PMC] [PubMed] [Google Cendekia]
Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C,
Smith R, Conrad A, Kleinman SH, dkk. 2003. Dinamika viremia HIV dan serokonversi
antibodi pada donor plasma: Implikasi untuk diagnosis dan penentuan stadium infeksi HIV
primer. AIDS 17: 1871–1879 [PubMed] [Google Cendekia]
Fischer W, Ganusov VV, Giorgi EE, PT Hraber, Keele BF, Leitner T, Han CS, CD Penghibur,
Green L, Lo CC, dkk. 2010. Transmisi genom HIV-1 tunggal dan dinamika pelarian
kekebalan dini yang diungkapkan oleh sekuensing ultra-dalam. PLoS One 5: e12303. [Artikel
gratis PMC] [PubMed] [Google Cendekia]
Fischetti L, Barry SM, Hope TJ, Shattock RJ 2009. Infeksi HIV-1 jaringan eksplan penis
manusia dan perlindungan oleh kandidat mikrobisida. AIDS 23: 319–328 [Artikel gratis
PMC] [PubMed] [Google Cendekia]
Fletcher P, Kiselyeva Y, Wallace G, Romano J, Griffin G, Margolis L, Shattock R 2005.
Penghambat transkriptase nukleosida non-nukleosida UC-781 menghambat infeksi virus
imunodefisiensi manusia tipe 1 pada jaringan serviks manusia dan penyebaran oleh sel-sel
migrasi. J Virol 79: 11179–11186 [artikel gratis PMC] [PubMed] [Google Cendekia]
Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ 2006. Ex
vivo kultur jaringan kolorektal manusia untuk evaluasi kandidat mikrobisida. AIDS 20:
1237–1245 [PubMed] [Google Cendekia]
Frost SD, Liu Y, Pond SL, Chappey C, Wrin T, Petropoulos CJ, Little SJ, Richman DD 2005.
Karakterisasi variasi virus human immunodeficiency type 1 (HIV-1) dan menetralkan
tanggapan antibodi selama transmisi subtipe HIV-1 B. J Virol 79: 6523-6527 [Artikel gratis
PMC] [PubMed] [Google Cendekia]
72
Gaines H, von Sydow M, Pehrson PO, Lundbegh P 1988. Gambaran klinis infeksi HIV
primer muncul sebagai penyakit mirip demam kelenjar. BMJ 297: 1363–1368 [artikel gratis
PMC] [PubMed] [Google Cendekia]
Galvin SR, Cohen MS 2004. Peran penyakit menular seksual dalam penularan HIV. Nat Rev
Microbiol 2: 33–42 [PubMed] [Google Cendekia]
Gilbert MT, Rambaut A, Wlasiuk G, Spira TJ, Pitchenik AE, Worobey M 2007. Munculnya
HIV / AIDS di Amerika dan sekitarnya. Proc Natl Acad Sci 104: 18566–18570 [artikel gratis
PMC] [PubMed] [Google Cendekia]
Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, PT Hraber, Lapedes AS, Shen T,
Gaschen B, Krishnamoorthy M, Li H, Decker JM 2011. Pola tanda tangan berulang dalam
glikoprotein amplop clade HIV-1 B yang terkait dengan awal atau infeksi kronis. PloS Pathog
7: e1002209. [Artikel gratis PMC] [PubMed] [Google Cendekia]
Grey RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F,
Lutalo T, Li X, vanCott T, Quinn TC 2001. Kemungkinan penularan HIV-1 per tindakan
coiter secara monogami, heteroseksual, HIV-1 -Diskordan pasangan di Rakai, Uganda.
Lancet 357: 1149–1153 [PubMed] [Google Cendekia]
Grey RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, Nalugoda F,
Kiddugavu M, Sewankambo N, Quinn TC, dkk. 2005. Peningkatan risiko kejadian HIV
selama kehamilan di Rakai, Uganda: Sebuah studi prospektif. Lancet 366: 1182–1188
[PubMed] [Google Cendekia]
Grey RH, Kigozi G, Serwadda D, Makumbi F, Watya S, F Nalugoda, Kiwanuka N, Moulton
LH, Chaudhary MA, Chen MZ, dkk. 2007. Sunat pada pria untuk pencegahan HIV pada pria
di Rakai, Uganda: Sebuah uji coba acak. Lancet 369: 657-666 [PubMed] [Google Cendekia]
Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ 2000. Parameter infeksi
virus humanodefisiensi jaringan serviks manusia dan penghambatan oleh virucides vagina. J
Virol 74: 5577–5586 [artikel gratis PMC] [PubMed] [Google Cendekia]
Grivel JC, Elliott J, Lisco A, Biancoto A, Condack C, Shattock RJ, McGowan I, Margolis L,
Anton P 2007. Patogenesis HIV-1 berbeda dalam jaringan rectosigmoid dan tonsiler yang
terinfeksi ex vivo dengan CCR5- dan CXCR4-tropic HIV- 1. AIDS 21: 1263–1272 [PubMed]
[Google Cendekia]
Grobler J, Grey CM, Rademeyer C, Seoighe C, Ramjee G, Karim SA, Morris L, Williamson
C 2004. Insidensi infeksi ganda HIV-1 dan hubungannya dengan peningkatan titik viral load
dalam kelompok HIV-1 subtipe C Pekerja seks perempuan yang terinfeksi. J Infect Dis 190:
1355–1359 [PubMed] [Google Cendekia]
73
Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar S 2003.
Penipisan sel T CD4 + yang parah di jaringan limfoid usus selama infeksi virus
humanodefisiensi primer tipe 1 manusia dan keterlambatan substansial dalam pemulihan
setelah terapi antiretroviral yang sangat aktif. . J Virol 77: 11708–11717 [artikel gratis PMC]
[PubMed] [Google Cendekia]
Haaland RE, Hawkins PA, Salazar-Gonzalez J, Johnson A, Tichacek A, Karita E, Manigart O,
Mulenga J, Keele BF, Shaw GM, et al. 2009. Infeksi genital peradangan mengurangi
hambatan genetik yang parah pada penularan heteroseksual subtipe A dan C HIV-1. PLoS
Pathog 5: e1000274. [Artikel gratis PMC] [PubMed] [Google Cendekia]
Haase AT 2010. Menargetkan infeksi dini untuk mencegah penularan mukosa HIV-1. Alam
464: 217–223 [PubMed] [Google Cendekia]
Heise C, Miller CJ, Lackner A, Dandekar S 1994. Infeksi virus simian imunodefisiensi
primer akut dari jaringan limfoid usus dikaitkan dengan disfungsi gastrointestinal. J Infect
Dis 169: 1116–1120 [PubMed] [Google Cendekia]
Hemelaar J, Gouws E, Ghys PD, Osmanov S 2006. Distribusi subtipe dan rekombinan
genetik HIV-1 global dan regional pada tahun 2004. AIDS 20: W13-W23 [PubMed] [Google
Scholar]
Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM,
Landucci G, Forthal DN, Parren PW, dkk. 2007. Reseptor Fc tetapi tidak mengikat mengikat
penting dalam perlindungan antibodi terhadap HIV. Alam 449: 101–104 [PubMed] [Google
Cendekia]
Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK Parren PW, Marx
PA, Burton DR 2009a. Perlindungan antibodi titer rendah yang efektif terhadap tantangan
SHIV mukosa dosis rendah di kera. Nat Med 15: 951–954 [Artikel gratis PMC] [PubMed]
[Google Cendekia]
Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, DN Forthal, Koff WC,
Watkins DI, Burton DR 2009b. Antibodi anti-HIV manusia 2G12 yang secara luas
dinetralkan efektif dalam perlindungan terhadap tantangan SHIV mukosa bahkan pada titer
penetralisir serum yang rendah. PLoS Pathog 5: e1000433. [Artikel gratis PMC] [PubMed]
[Google Cendekia]
Hladik F, McElrath MJ 2008. Mengatur panggung: Host invasi oleh HIV. Nat Rev Immunol
8: 447–457 [artikel gratis PMC] [PubMed] [Google Cendekia]
Hladik F, P Sakchalathorn, Ballweber L, Lentz G, Fialkow M, Eschenbach D, McElrath MJ
2007. Peristiwa awal dalam membangun entri vagina dan infeksi oleh human
74
immunodeficiency virus tipe-1. Kekebalan 26: 257–270 [artikel gratis PMC] [PubMed]
[Google Cendekia]
Hu J, Gardner MB, Miller CJ 2000. Virus imunodefisiensi Simian dengan cepat menembus
mukosa serviks setelah inokulasi intravaginal dan menginfeksi sel dendritik intraepitel. J
Virol 74: 6087–6095 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE, Moore JP, Paus M, Shattock RJ
2004. Blokade pelekatan dan reseptor fusi menghambat infeksi HIV-1 pada jaringan serviks
manusia. J Exp Med 199: 1065-1075 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Hudgens MG, Longini IM Jr, Vanichseni S, Hu DJ, D Kitayaporn, PA Mock, Halloran ME,
Satten GA, Choopanya K, Mastro TD 2002. Kemungkinan penularan subtipe khusus untuk
human immunodeficiency virus tipe 1 di antara pengguna narkoba suntikan di Bangkok,
Thailand. Am J Epidemiol 155: 159–168 [PubMed] [Google Cendekia]
Isaacman-Beck J, Hermann EA, Yi Y, Ratcliffe SJ, Mulenga J, Allen S, Hunter E, Derdeyn
CA, Collman RG 2009. Penularan heteroseksual dari virus human defisiensi imun tipe 1
subtipe C: tropisme makrofag, penggunaan koroseptor alternatif, dan anatomi molekul
pemanfaatan CCR5. J Virol 83: 8208–8220 [Artikel gratis PMC] [PubMed] [Google
Cendekia]
Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S,
Shankarappa R, Margolick JB, Mullins JI 2003. Peningkatan prediksi penggunaan coreceptor
dan pemantauan genotip transisi R5-ke-X4 dengan motif analisis human immunodeficiency
virus tipe 1 env V3 urutan lingkaran. J Virol 77: 13376–13388 [Artikel gratis PMC]
[PubMed] [Google Cendekia]
Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, Mattapallil JJ 2009. α4 + β7
(hi) memori CD4 + sel T memendam sebagian besar sel Th-17 dan lebih disukai terinfeksi
selama infeksi SIV akut. Mucosal Immunol2: 439-449 [artikel gratis PMC] [PubMed]
[Google Cendekia]
Kearney M, Maldarelli F, Shao W, Margolick JB, Daar ES, Mellors JW, Rao V, Coffin JM,
Palmer S 2009. Virus human immunodeficiency virus tipe 1 populasi genetika dan adaptasi
pada individu yang baru terinfeksi. J Virol 83: 2715–2727 [Artikel gratis PMC] [PubMed]
[Google Cendekia]
Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, Sun C,
Grayson T, Wang S, Li H, et al. 2008. Identifikasi dan karakterisasi amplop virus penularan
dan pendiri awal pada infeksi HIV-1 primer. Proc Natl Acad Sci 105: 7552-7557 [Artikel
gratis PMC] [PubMed] [Google Cendekia]
75
Keele BF, Li H, Belajar GH, Hraber P, Giorgi EE, Grayson T, Sun C, Chen Y, Yeh WW,
Letvin NL, dkk. 2009. Inokulasi dubur dosis rendah kera rhesus oleh SIVsmE660 atau
SIVmac251 merekapitulasi infeksi mukosa manusia oleh HIV-1. J Exp Med 206: 1117-1134
[Artikel gratis PMC] [PubMed] [Google Cendekia]
Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S,
Bhattacharya T 2000. Memperkecil leluhur dari strain pandemi HIV-1. Sains 288: 1789–1796
[PubMed] [Google Cendekia]
Kotler DP, HP Gaetz, Lange M, Klein EB, Holt PR 1984. Enteropati terkait dengan sindrom
imunodefisiensi yang didapat. Ann Intern Med 101: 421–428 [PubMed] [Google Cendekia]
Kouyos RD, von Wyl V, Yerly S, Boni J, Taffe P, Shah C, Burgisser P, Klimkait T, Weber R,
Hirschel B, dkk. 2010. Epidemiologi molekuler mengungkapkan perubahan jangka panjang
dalam penularan subtipe B tipe 1 HIV di Swiss. J Infect Dis 201: 1488–1497 [PubMed]
[Google Cendekia]
Pelajari GH, Muthui D, Brodie SJ, Zhu T, Diem K, Mullins JI, Corey L 2002. Homogenisasi
populasi virus setelah infeksi akut human immunodeficiency virus tipe 1. J Virol 76: 11953–
11959 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Lee HY, Giorgi EE, Keele BF, Gaschen B, Athreya GS, Salazar-Gonzalez JF, Pham KT,
Goepfert PA, Kilby JM, Saag MS, dkk. 2009. Memodelkan urutan evolusi pada infeksi HIV-1
akut. J Theor Biol 261: 341–360 [artikel gratis PMC] [PubMed] [Google Cendekia]
Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, P Goepfert,
Gilbert P, Greene KM, dkk. 2005a. Human immunodeficiency virus tipe 1 klon env dari
infeksi subtipe B akut dan awal untuk penilaian standar dari antibodi penetralisir yang
ditimbulkan oleh vaksin. J Virol 79: 10108–10125 [artikel gratis PMC] [PubMed] [Google
Cendekia]
Li Q, Duan L, Estes JD, Ma ZM, Rourke T, Wang Y, Reilly C, Carlis J, Miller CJ, Haase AT
2005b. Replikasi SIV puncak dalam memori istirahat sel T CD4 + menghabiskan usus lamina
propria sel T CD4 +. Alam 434: 1148–1152 [PubMed] [Google Cendekia]
Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM,
Li Y, Salazar MG, Polonis VR, dkk. 2006. Sifat genetik dan netralisasi subtipe C human
immunodeficiency virus tipe 1 klon env molekul dari infeksi heteroseksual akut dan awal
yang didapat di Afrika Selatan. J Virol 80: 11776–11790 [artikel gratis PMC] [PubMed]
[Google Cendekia]
Li Q, Estes JD, Duan L, Jessurun J, Pambucia S, C Forster, Wietgrefe S, Zupancic M,
Schacker T, Reilly C, dkk. 2008. Simian immunodeficiency virus-induced sel usus apoptosis
76
adalah mekanisme yang mendasari enteropati regeneratif infeksi awal. J Infect Dis 197: 420–
429 [PubMed] [Google Cendekia]
Li Q, Estes JD, PM Schlievert, Duan L, Brosnahan AJ, PJ Selatan, Reilly CS, Peterson ML,
Schultz-Darken N, Brunner KG, dkk. 2009a. Gliserol monolaurat mencegah transmisi SIV
mukosa. Nature 458: 1034-1038 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Li Q, Smith AJ, Schacker TW, Carlis JV, Duan L, Reilly CS, Haase AT 2009b. Analisis
microarray dari jaringan limfatik menunjukkan tanda-tanda ekspresi gen spesifik pada tahap
infeksi HIV-1. J Immunol 183: 1975–1982 [artikel gratis PMC] [PubMed] [Google Cendekia]
Li H, Bar KJ, Wang S, JM Decker, Chen Y, Sun C, Salazar-Gonzalez JF, Salazar MG, Belajar
GH, Morgan CJ, dkk. 2010. Infeksi multiplisitas tinggi oleh HIV-1 pada pria yang
berhubungan seks dengan pria. PLoS Pathog 6: e1000890. [Artikel gratis PMC] [PubMed]
[Google Cendekia]
Lifson JD, Nowak MA, Goldstein S, Rossio JL, Kinter A, Vasquez G, TA Wiltrout, Brown C,
Schneider D, Wahl L, dkk. 1997. Tingkat replikasi virus awal adalah penentu penting dari
sejarah alami infeksi virus simian immunodeficiency virus. J Virol 71: 9508–9514 [artikel
gratis PMC] [PubMed] [Google Cendekia]
Lindback S, AC Karlsson, Mittler J, Blaxhult A, Carlsson M, Briheim G, Sonnerborg A,
Gaines H 2000a. Dinamika virus pada infeksi HIV-1 primer. Kelompok Studi Infeksi HIV
Primer Institut Karolinska. AIDS14: 2283–2291 [PubMed] [Google Cendekia]
Lindback S, Thorstensson R, AC Karlsson, von Sydow M, Flamholc L, Blaxhult A,
Sonnerborg A, Biberfeld G, Gaines H 2000b. Diagnosis infeksi HIV-1 primer dan masa
tindak lanjut setelah pajanan HIV. Kelompok Studi Infeksi HIV Primer Karolinska Institute.
AIDS 14: 2333–2339 [PubMed] [Google Cendekia]
Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV 1999. Dinamika virus dari infeksi
HIV-1 akut. J Exp Med 190: 841–850 [artikel gratis PMC] [PubMed] [Google Cendekia]
Liu J, Keele BF, Li H, Keating S, Norris PJ, Carville A, Mansfield KG, Tomaras GD, Haynes
BF, Kolodkin-Gal D, dkk. 2010. Infeksi virus simian imunodefisiensi mukosa dosis rendah
membatasi kinetika replikasi awal dan varian virus yang ditransmisikan pada monyet rhesus.
J Virol 84: 10406–10412 [artikel gratis PMC] [PubMed] [Google Cendekia]
EM Panjang, Martin HL Jr, Kreiss JK, Rainwater SM, Lavreys L, Jackson DJ, Rakwar J,
Mandaliya K, Overbaugh J 2000. Perbedaan gender dalam keragaman HIV-1 pada saat
infeksi. Nat Med 6: 71–75 [PubMed] [Google Cendekia]
77
Ma Z, Lu FX, Torten M, Miller CJ 2001. Jumlah dan distribusi sel-sel kekebalan pada
mukosa serviks tetap konstan sepanjang siklus menstruasi kera rhesus. Clin Immunol 100:
240–249 [PubMed] [Google Cendekia]
Ma ZM, Batu M, Piatak M Jr, Schweighardt B, Haigwood NL, Montefiori D, Lifson JD,
Busch MP, Miller CJ 2009. Infektivitas spesifik tinggi dari virus plasma dari tahap pra-ramp-
up dan ramp-up simian akut infeksi virus imunodefisiensi. J Virol 83: 3288–3297 [artikel
gratis PMC] [PubMed] [Google Cendekia]
Ma Z-M, BF Keele, Qureshi H, Batu M, DeSilva V, Fritts L, Lifson JD, Miller CJ 2011.
SIVmac251 tidak efisien ditransmisikan ke kera rhesus dengan inokulasi penis dengan varian
SIVenv tunggal yang ditemukan dalam plasma fase ramp-up. AIDS Res Hum Retroviruses
10.1089 / aid.2011.0090 [Artikel gratis PMC] [PubMed] [CrossRef] [Google Cendekia]
Maher D, Wu X, T Schacker, Horbul J, Southern P 2005. Ikatan HIV, penetrasi, dan infeksi
primer pada jaringan serviks manusia. Proc Natl Acad Sci 102: 11504–11509 [Artikel gratis
PMC] [PubMed] [Google Cendekia]
* Malim MH, Bieniasz PD 2011. Faktor pembatasan HIV dan mekanisme penghindaran.
Cold Spring Harb Perspect Med 10.1101 / cshperspect.a006940 [artikel gratis PMC]
[PubMed] [CrossRef] [Google Cendekia]
Mascola JR 2002. Studi transfer pasif untuk menjelaskan peran perlindungan yang dimediasi
antibodi terhadap HIV-1. Vaksin 20: 1922–1925 [PubMed] [Google Cendekia]
Masharsky AE, Dukhovlinova EN, Verevochkin SV, Toussova OV, RV Skochilov, Anderson
JA, Hoffman I, Cohen MS, Swanstrom R, Kozlov AP 2010. Hambatan transmisi yang
substansial di antara pengguna narkoba suntikan yang baru dan baru terinfeksi HIV di St
Petersburg , Rusia. J Infect Dis 201: 1697–1702 [PubMed] [Google Cendekia]
Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M 2005. Infeksi besar-
besaran dan kehilangan memori sel CD4 + T di banyak jaringan selama infeksi SIV akut.
Alam 434: 1093–1097 [PubMed] [Google Cendekia]
McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter
DK, Hural J, Akondy R, dkk. 2008. Imunitas yang diinduksi vaksin HIV-1 dalam studi
langkah uji konsep: Analisis kohort kasus. Lancet 372: 1894–1905 [artikel gratis PMC]
[PubMed] [Google Cendekia]
Mehandru S, Polandia MA, Tenner-Racz K, Horowitz A, Hurley A, Hogan C, Boden D, Racz
P, Markowitz M 2004. Infeksi HIV-1 primer dikaitkan dengan penipisan sel limfosit T CD4 +
yang dipilih dari tempat efektor di saluran pencernaan di saluran pencernaan. sistem. J Exp
Med 200: 761-770 [Artikel gratis PMC] [PubMed] [Google Cendekia]
78
Merbah M, Introini A, Fitzgerald W, Grivel JC, Lisco A, Vanpouille C, Margolis L 2011.
Exvivo jaringan cervico-vaginal sebagai model untuk mempelajari peristiwa awal infeksi
HIV-1. Am J Reprod Immunol 65: 268-278 [artikel gratis PMC] [PubMed] [Google
Cendekia]
Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L,
Duan L, Shore MD, dkk. 2005. Perbanyakan dan penyebaran infeksi setelah penularan
melalui vagina virus simian immunodeficiency. J Virol 79: 9217–9227 [Artikel gratis PMC]
[PubMed] [Google Cendekia]
Miller WC, Rosenberg NE, Rutstein SE, Powers KA 2010. Peran infeksi HIV akut dan dini
dalam penularan HIV secara seksual. Curr Opin HIV AIDS 5: 277–282 [artikel gratis PMC]
[PubMed] [Google Cendekia]
Miyake A, Ibuki K, Enose Y, Suzuki H, Horiuchi R, Motohara M, Saito N, Nakasone T,
Honda M, Watanabe T, dkk. 2006. Penyebaran cepat virus patian simian / human
immunodeficiency virus ke organ sistemik dan replikasi aktif dalam jaringan limfoid setelah
infeksi intrarektal. J Gen Virol 87: 1311–1320 [PubMed] [Google Cendekia]
Nawaz F, Cicala C, Van Ryk D, Blok KE, Jelicic K, McNally JP, Ogundare O, Pascuccio M,
Patel N, Wei D, et al. 2011. Genotipe penularan HIV gp120s dini mempromosikan reaktivitas
αβ, mengungkapkan sel T αβCD4 + sebagai target utama dalam transmisi mukosa. PLoS
Pathog 7: e1001301. [Artikel gratis PMC] [PubMed] [Google Cendekia]
Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J,
Kinter A, Fauci AS, Hirsch VM, dkk. 1997. Dinamika virus dari viremia primer dan terapi
antiretroviral pada infeksi virus simian immunodeficiency virus. J Virol 71: 7518–7525
[Artikel gratis PMC] [PubMed] [Google Cendekia]
CT Nugent, Dockter J, F Bernardin, Hecht R, D Smith, Delwart E, Pilcher C, Richman D,
Busch M, Giachetti C 2009. Deteksi HIV-1 pada jenis spesimen alternatif menggunakan Uji
Kualitatif RNA APTIMA HIV-1. J Metode Virol 159: 10–14 [Artikel gratis PMC] [PubMed]
[Google Cendekia]
Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu
S, Metcalf JA, dkk. 2003. Uji PCR reverse transcriptase yang diprakarsai secara real-time
baru dengan sensitivitas satu salinan untuk RNA virus 1 tipe human immunodeficiency
manusia dalam plasma. J Clin Microbiol 41: 4531–4536 [artikel gratis PMC] [PubMed]
[Google Cendekia]
79
Pearson JE, Krapivsky P, Perelson AS 2011. Teori stokastik infeksi virus awal: Produksi
virion yang terus-menerus versus meledak. PLoS Comput Biol 7: e1001058. [Artikel gratis
PMC] [PubMed] [Google Cendekia]
Paus M, Haase AT 2003. Penularan, infeksi HIV-1 akut dan pencarian strategi untuk
mencegah infeksi. Nat Med 9: 847–852 [PubMed] [Google Cendekia]
Poss M, Martin HL, Kreiss JK, Granville L, Chohan B, Nyange P, Mandaliya K, Overbaugh J
1995. Keragaman dalam populasi virus dari sekresi genital dan darah tepi dari wanita yang
baru-baru ini terinfeksi virus human immunodeficiency type 1. J Virol 69: 8118–8122 [artikel
gratis PMC] [PubMed] [Google Cendekia]
Powers KA, Poole C, Pettifor AE, Cohen MS 2008. Memikirkan kembali infektivitas
heteroseksual HIV-1: Tinjauan sistematis dan meta analisis. Lancet Infect Dis 8: 553–563
[artikel gratis PMC] [PubMed] [Google Cendekia]
Pudney J, Quayle AJ, Anderson DJ 2005. Lingkungan mikro imunologis pada vagina dan
leher rahim manusia: Mediator imunitas seluler terkonsentrasi di zona transformasi serviks.
Biol Reprod 73: 1253–1263 [PubMed] [Google Cendekia]
Quinn TC 2007. Sunat dan penularan HIV. Curr Opin Infect Dis 20: 33-38 [PubMed] [Google
Cendekia]
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan
MO, Lutalo T, Grey RH 2000. Viral load dan penularan heteroseksual dari virus human
immunodeficiency virus tipe 1. Kelompok Studi Proyek Rakai. N Engl J Med 342: 921–929
[PubMed] [Google Cendekia]
Resch W, Hoffman N, Swanstrom R 2001. Peningkatan keberhasilan prediksi fenotipe virus
human immunodeficiency type 1 dari urutan variabel loop 3 menggunakan jaringan saraf.
Virology288: 51-62 [PubMed] [Google Cendekia]
Ribeiro RM, Qin L, Chavez LL, Li D, SG Sendiri, Perelson AS 2010. Perkiraan tingkat
pertumbuhan virus awal dan jumlah reproduksi dasar selama infeksi HIV-1 akut. J Virol 84:
6096-6102 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Richman DD, Wrin T, Little SJ, Petropoulos CJ 2003. Evolusi cepat dari respon antibodi
penawar terhadap infeksi HIV tipe 1. Proc Natl Acad Sci 100: 4144-4149 [Artikel gratis
PMC] [PubMed] [Google Cendekia]
Ridzon R, Gallagher K, Ciesielski C, Ginsberg MB, Robertson BJ, Luo CC, DeMaria A Jr,
1997. Penularan serentak virus human immunodeficiency virus dan virus hepatitis C dari luka
akibat jarum suntik. N Engl J Med 336: 919–922 [PubMed] [Google Cendekia]
80
Ritola K, Pilcher CD, Fiscus SA, Hoffman NG, Nelson JA, Kitrinos KM, Hicks CB, Eron JJ
Jr, Swanstrom R 2004. Varian ganda V1 / V2 sering ditemukan selama infeksi primer dengan
jenis virus kekurangan kekebalan manusia tipe 1. J Virol 78: 11208–11218 [artikel gratis
PMC] [PubMed] [Google Cendekia]
Russell ES, Kwiek JJ, Tombol J, Barton K, Mwapasa V, Montefiori DC, Meshnick SR,
Swanstrom R 2011. Hambatan genetik dalam transmisi vertikal subtipe C HIV-1 tidak
didorong oleh pilihan virus yang sangat netral terhadap virus. populasi virus ibu. J Virol 85:
8253–8262 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Saba E, Grivel JC, Vanpouille C, Brichacek B, Fitzgerald W, Margolis L, Lisco A 2010.
Penularan seksual HIV-1: Kejadian awal infeksi HIV-1 jaringan serviks-vagina manusia
dalam model ex vivo yang dioptimalkan. Mucosal Immunol 3: 280–290 [artikel gratis PMC]
[PubMed] [Google Cendekia]
Sacktor N, Nakasujja N, Skolasky RL, Rezapour M, Robertson K, Musisi S, Katabira E,
Ronald A, Clifford DB, Laeyendecker O, dkk. 2009. Subtipe HIV dikaitkan dengan
demensia, dibandingkan dengan subtipe A, pada orang yang tertekan imun yang berisiko
mengalami gangguan kognitif di Kampala, Uganda. Clin Infect Dis 49: 780-786 [artikel
gratis PMC] [PubMed] [Google Cendekia]
Sagar M, Kirkegaard E, Long EM, Celum C, Buchbinder S, Daar ES, Overbaugh J 2004.
Keragaman human immunodeficiency virus tipe 1 (HIV-1) pada saat infeksi tidak terbatas
pada kelompok risiko tertentu atau subtipe HIV-1 tertentu. . J Virol 78: 7279-7283 [Artikel
gratis PMC] [PubMed] [Google Cendekia]
Sagar M, Laeyendecker O, Lee S, Gamiel J, Maw Wawer, Grey RH, Serwadda D,
Sewankambo NK, JC Gembala, Toma J, dkk. 2009. Pemilihan varian HIV dengan
karakteristik genotip khas selama transmisi heteroseksual. J Infect Dis 199: 580–589 [artikel
gratis PMC] [PubMed] [Google Cendekia]
Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, MB Guffey, Keele BF, Derdeyn CA,
Petani P, Hunter E, Allen S, dkk. 2008. Menguraikan transmisi human immunodeficiency
virus tipe 1 dan diversifikasi amplop awal dengan amplifikasi dan sekuensing genom tunggal.
J Virol 82: 3952–3970 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Salazar-Gonzalez JF, Salazar MG, Keele BF, Belajar GH, Giorgi EE, Li H, Decker JM, Wang
S, Baalwa J, Kraus MH, dkk. 2009. Identitas genetik, fenotip biologis, dan jalur evolusi dari
virus yang ditularkan / pendiri pada infeksi HIV-1 akut dan dini. J Exp Med 206: 1273-1289
[Artikel gratis PMC] [PubMed] [Google Cendekia]
81
Schacker T, Collier AC, Hughes J, Shea T, Corey L 1996. Gambaran klinis dan epidemiologis
dari infeksi HIV primer. Ann Intern Med 125: 257–264 [PubMed] [Google Cendekia]
Schacker T, Little S, Connick E, Gebhard K, Zhang ZQ, Krieger J, Pryor J, Havlir D, Wong
JK, Schooley RT, dkk. 2001. Infeksi sel T yang produktif dalam jaringan limfoid selama
infeksi virus humanodeodefisiensi primer dan awal manusia. J Infect Dis 183: 555–562
[PubMed] [Google Cendekia]
* Sharp PM, Hahn BH 2011. Asal-usul HIV dan pandemi AIDS. Cold Spring Harbor Perspect
Med [Artikel gratis PMC] [PubMed] [Google Cendekia]
Shen R, HE Richter, Clements RH, Novak L, Huff K, Bimczok D, Sankaran-Walters S,
Dandekar S, Clapham PR, Smythies LE, dkk. 2009. Makrofag pada mukosa vagina tetapi
bukan usus bersifat monosit dan permisif terhadap infeksi virus human defisiensi tipe 1. J
Virol 83: 3258–3267 [Artikel gratis PMC] [PubMed] [Google Cendekia]
Shen R, Smythies LE, Clements RH, Novak L, Smith PD 2010. Sel dendritik menularkan
HIV-1 melalui mukosa usus kecil manusia. J Leukoc Biol 87: 663–670 [artikel gratis PMC]
[PubMed] [Google Cendekia]
Stone M, Keele BF, Ma ZM, Bailes E, Dutra J, Hahn BH, Shaw GM, Miller CJ 2010.
Sejumlah terbatas varian virus simian immunodeficiency (SIV) ditransmisikan ke kera rhesus
yang diinokulasi secara vagina dengan SIVmac251. J Virol 84: 7083–7095 [Artikel gratis
PMC] [PubMed] [Google Cendekia]
Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM 2008. Tantangan keragaman
subtipe HIV-1. N Engl J Med 358: 1590–1602 [Artikel gratis PMC] [PubMed] [Google
Cendekia]
UNAIDS 2010. Laporan Global 2010, Jenewa.
http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf
Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M,
RP Johnson, RC Desrosiers, Lackner AA 1998. Saluran gastrointestinal sebagai situs utama
penipisan sel T CD4 + dan replikasi virus pada infeksi SIV. Sains 280: 427–431 [PubMed]
[Google Cendekia]
Wawer MJ, Grey RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N,
Kigozi G, Kiddugavu M, Lutalo T, dkk. 2005. Tingkat penularan HIV-1 per tindakan coital,
pada tahap infeksi HIV-1, di Rakai, Uganda. J Infect Dis 191: 1403–1409 [PubMed] [Google
Cendekia]
82
Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG,
Kilby JM, Saag MS, dkk. 2003. Netralisasi dan pelarian antibodi oleh HIV-1. Alam 422: 307–
312 [PubMed] [Google Cendekia]
Wilen CB, Parrish NF, Pfaff JM, JM Decker, Henning EA, Haim H, Sodroski J, Haynes BF,
Montefiori DC, Tilton JC, dkk. 2011a. Perbandingan fenotipik dan imunologis dari clade B
yang ditransmisikan / pendiri dan glikoprotein amplop HIV-1 kronis. J Virol (cetak) [Artikel
gratis PMC] [PubMed] [Google Cendekia]
* Wilen CB, Tilton JC, Doms RW 2011b. Mengikat dan masuk sel. Cold Spring Harbor
Perspect Med10.1101 / cshperspect.a006866 [artikel gratis PMC] [PubMed] [CrossRef]
[Google Cendekia]
Wira CR, Veronese F 2011. Penularan HIV secara seksual pada abad ke-21. Am J Reprod
Immunol 65: 181–376 [Google Cendekia]
Wolfs TF, Zwart G, Bakker M, Goudsmit J 1992. Diversifikasi RNA genomik HIV-1 setelah
penularan virus seksual dan parenteral. Virologi 189: 103–110 [PubMed] [Google Cendekia]
Wolinsky SM, Wike CM, Korber BT, Hutto C, Taman WP, Rosenblum LL, Kunstman KJ,
MR Furtado, Munoz JL 1992. Transmisi selektif varian human immunodeficiency virus tipe-
1 dari ibu ke bayi. Sains 255: 1134-1137 [PubMed] [Google Cendekia]
Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, Bunce M, Muyembe JJ,
Kabongo JM, Kalengayi RM, Van Marck E, dkk. 2008. Bukti langsung tentang keragaman
luas HIV-1 di Kinshasa pada tahun 1960. Alam 455: 661-664 [artikel gratis PMC] [PubMed]
[Google Cendekia]
Yeh WW, Rao SS, Lim S-Y, Zhang J, PT Hraber, Brassard LM, Luedemann C, Todd JP,
Dodson A, Shen L 2011. Gen TRIM5 memodulasi akuisisi mukosa penis dari virus
immunodefisiensi simian pada monyet Rhesus. J Virol 85: 10389-10398 [Artikel gratis PMC]
[PubMed] [Google Cendekia]
Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P 1993. Seleksi
untuk sekuens spesifik dalam protein amplop eksternal virus human immunodeficiency virus
tipe 1 pada infeksi primer. J Virol 67: 3345–3356 [artikel gratis PMC] [PubMed] [Google
Cendekia]
Zhang Z, Schuler T, Zupancic M, Wietgrefe S, Staskus KA, Reimann KA, Reinhart TA,
Rogan M, Cavert W, Miller CJ, dkk. 1999. Penularan dan penyebaran SIV dan HIV secara
seksual dalam sel T CD4 + yang beristirahat dan diaktifkan. Sains 286: 1353–1357 [PubMed]
[Google Cendekia]
83
Zhang ZQ, Wietgrefe SW, Li Q, MD Shore, Duan L, Reilly C, JD Lifson, Haase AT 2004.
Peran ketersediaan substrat dan infeksi sel T CD4 + yang diaktifkan dan diaktifkan dalam
transmisi dan infeksi virus simian imunodefisiensi akut. Proc Natl Acad Sci 101: 5640–5645
[artikel gratis PMC] [PubMed] [Google Cendekia]
Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD 1993. Karakterisasi genotipik dan
fenotipik pasien HIV-1 dengan infeksi primer. Sains 261: 1179–1181 [PubMed] [Google
Cendekia]
Zhu T, Wang N, Carr A, Nam DS, Moor-Jankowski R, Cooper DA, Ho DD 1996.
Karakterisasi genetik virus human immunodeficiency type 1 dalam darah dan sekresi genital:
Bukti untuk kompartementalisasi virus dan seleksi selama transmisi seksual. J Virol 70:
3098–3107 [artikel gratis PMC] [PubMed] [Google Cendekia]
84